<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cold Spring Harb Mol Case Stud</journal-id>
<journal-id journal-id-type="iso-abbrev">Cold Spring Harb Mol Case Stud</journal-id>
<journal-id journal-id-type="hwp">cshmcs</journal-id>
<journal-id journal-id-type="pmc">cshmcs</journal-id>
<journal-id journal-id-type="publisher-id">cshmcs</journal-id>
<journal-title-group>
<journal-title>Cold Spring Harbor Molecular Case Studies</journal-title>
</journal-title-group>
<issn pub-type="epub">2373-2873</issn>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30755392</article-id>
<article-id pub-id-type="pmc">6549575</article-id>
<article-id pub-id-type="doi">10.1101/mcs.a003756</article-id>
<article-id pub-id-type="medline">MCS003756Ji</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Precision Medicine in Practice</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A semiautomated whole-exome sequencing workflow leads to increased diagnostic yield and identification of novel candidate variants</article-title>
<alt-title alt-title-type="left-running">Whole-exome sequencing of pediatric patients</alt-title>
<alt-title alt-title-type="right-running">Whole-exome sequencing of pediatric patients</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ji</surname>
<given-names>Jianling</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shen</surname>
<given-names>Lishuang</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bootwalla</surname>
<given-names>Moiz</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Quindipan</surname>
<given-names>Catherine</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tatarinova</surname>
<given-names>Tatiana</given-names>
</name>
<xref ref-type="aff" rid="af3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Maglinte</surname>
<given-names>Dennis T.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Buckley</surname>
<given-names>Jonathan</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Raca</surname>
<given-names>Gordana</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Saitta</surname>
<given-names>Sulagna C.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Biegel</surname>
<given-names>Jaclyn A.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gai</surname>
<given-names>Xiaowu</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
</contrib-group>
<aff id="af1"><label>1</label>Center for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California 90027, USA;</aff>
<aff id="af2"><label>2</label>Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA;</aff>
<aff id="af3"><label>3</label>Department of Biology, University of La Verne, La Verne, California 91750, USA</aff>
<author-notes>
<corresp>Corresponding author: <email>xgai@chla.usc.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>4</month>
<year>2019</year>
</pub-date>
<volume>5</volume>
<issue>2</issue>
<elocation-id>a003756</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>11</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>6</day>
<month>2</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>
<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.cshlp.org/site/misc/terms.xhtml">© 2019 Ji et al.; Published by Cold Spring Harbor Laboratory Press</ext-link>
</copyright-statement>
<copyright-year>2019</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-NonCommercial License</ext-link>, which permits reuse and redistribution, except for commercial purposes, provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="MCS003756Ji.pdf"></self-uri>
<abstract>
<p>Advancing the clinical utility of whole-exome sequencing (WES) for patients with suspected genetic disorders is largely driven by bioinformatics approaches that streamline data processing and analysis. Herein, we describe our experience with implementing a semiautomated and phenotype-driven WES diagnostic workflow, incorporating both the DRAGEN pipeline and the Exomiser variant prioritization tool, at an academic children's hospital with an ethnically diverse pediatric patient population. We achieved a 41% molecular diagnostic rate for 66 duo-, quad-, or trio-WES cases, and 28% for 40 singleton-WES cases. Preliminary results were returned to ordering physicians within 1 wk for 12 of 38 (32%) probands with positive findings, which were instrumental in guiding the appropriate clinical management for a variety of patients, especially in critical care settings. The semiautomated and streamlined WES workflow also enabled us to identify novel variants in candidate disease genes in patients with developmental delay and autism and immune disorders and cancer, including <italic>ANK2</italic>, <italic>BPTF</italic>, <italic>BCL11A</italic>, <italic>FOXN1</italic>, <italic>PLAA, ATRX, DNAJC21</italic>, and <italic>RAD50</italic>. Together, we demonstrated the implementation of a streamlined WES workflow that was successfully applied for both clinical and research purposes.</p>
</abstract>
<kwd-group>
<kwd>abnormality of the cerebral vasculature</kwd>
<kwd>acute myeloid leukemia</kwd>
<kwd>aggressive behavior</kwd>
<kwd>ambiguous genitalia, male</kwd>
<kwd>aplasia of the thymus</kwd>
<kwd>astrocytoma</kwd>
<kwd>ataxia</kwd>
<kwd>autism</kwd>
<kwd>bilateral cryptorchidism</kwd>
<kwd>cleft palate</kwd>
<kwd>delayed social development</kwd>
<kwd>generalized hypotonia due to defect at the neuromuscular junction</kwd>
<kwd>generalized tonic seizures</kwd>
<kwd>microcephaly</kwd>
<kwd>osteosarcoma</kwd>
<kwd>retinoblastoma</kwd>
<kwd>severe T-cell immunodeficiency</kwd>
<kwd>severe global developmental delay</kwd>
<kwd>short stature</kwd>
<kwd>webbed neck</kwd>
</kwd-group>
<funding-group>
<award-group id="funding-1">
<funding-source>Department of Pathology and Laboratory Medicine at the Children's Hospital Los Angeles</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="19"></page-count>
</counts>
</article-meta>
</front>
<body><sec id="s1" sec-type="introduction"><title>INTRODUCTION</title><p>Whole-exome sequencing (WES) has been enormously successful for both novel disease gene discovery (<xref ref-type="bibr" rid="MCS003756JIC1">Bamshad et al. 2011</xref>; <xref ref-type="bibr" rid="MCS003756JIC21">Ku et al. 2012</xref>) and in the clinical diagnostic setting to determine the genetic causes of rare Mendelian (monogenic) disorders (<xref ref-type="bibr" rid="MCS003756JIC22">Lee et al. 2014</xref>; <xref ref-type="bibr" rid="MCS003756JIC34">Yang et al. 2014</xref>; <xref ref-type="bibr" rid="MCS003756JIC9">Farwell et al. 2015</xref>). Over the past few years, with the wide application of WES, a rich framework of experimental and analytical approaches has been established for elucidating the genes responsible for Mendelian disorders (<xref ref-type="bibr" rid="MCS003756JIC1">Bamshad et al. 2011</xref>). Technical and informatics advancements have led to reduced cost and turnaround time, as well as increased diagnostic yield and impact on patients’ outcomes. The success rate has varied significantly across laboratories primarily because of (1) technical differences in capturing and sequencing approaches, (2) the patient population being studied and possible ascertainment bias, (3) the availability of large reference databases, (4) the bioinformatics pipelines used, and, most importantly, (5) a highly variable practice of variant interpretation, which has been largely manual and has not consistently followed unified guidelines. The overall WES diagnostic rate in unselected, consecutive patients has been reported to be ∼25% (<xref ref-type="bibr" rid="MCS003756JIC22">Lee et al. 2014</xref>; <xref ref-type="bibr" rid="MCS003756JIC34">Yang et al. 2014</xref>; <xref ref-type="bibr" rid="MCS003756JIC9">Farwell et al. 2015</xref>; <xref ref-type="bibr" rid="MCS003756JIC6">Dragojlovic et al. 2018</xref>). The efficiency of data analysis is limited by the need for multiple manual data interpretation steps, limited communication with ordering physicians, and, most importantly, limited adaptation of robust informatics tools to facilitate prioritization of variants.</p><p>Herein, we describe our clinical and research findings with implementing a semiautomated and phenotype-driven WES diagnostic workflow at a large academic children's hospital with an ethnically diverse pediatric patient population. The workflow was implemented, validated, and optimized using validation samples with known molecular diagnoses and then applied prospectively to clinical cases. We implemented the Edico DRAGEN Genome pipeline for rapid (∼4-min) variant calling, used standardized phenotypic description Human Phenotype Ontology (HPO) terms for primary gene selection, and incorporated Exomiser for automated variant prioritization. Using these approaches, results can be obtained in 72 h and can thus positively impact patient management in critical care settings. This workflow has a proven ability to identify novel variants and novel candidate disease genes automatically, especially for patients with developmental and immunologic disorders.</p></sec><sec id="s2" sec-type="results"><title>RESULTS</title><sec id="s2a"><title>Clinical Presentation and Family History</title><p>The 106 clinical cases were referred from nine clinical divisions at the Children's Hospital Los Angeles including Medical Genetics (39), Neurology (26), Immunology (17), Neonatology and Pulmonology (12), Hematology &amp; Oncology (5), Endocrinology (3), Dermatology (2), General Pediatrics (1), and Ophthalmology (1) (<xref ref-type="fig" rid="MCS003756JIF1">Fig. 1</xref>A). These included 40 singletons (proband only), 60 trios (typically proband and both parents), 5 duos (proband and one parent), and 1 quad (proband, parents, and affected sibling). Of the 106 probands, there were 63 (59%) males and 43 (41%) females. Patients’ age at the time of referral varied from newborn to 22 yr (median age 3 yr) (<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Table 1</ext-link>). Patients presented with a range of phenotypes, as indicated by the 521 HPO terms mapped to patients’ clinical phenotypes (<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Table 1</ext-link>). The most common clinical indications included “global developmental delay” (29%), “seizures” (21%), “generalized hypotonia” (19%), “microcephaly” (10%), “cognitive impairment” (9%), “short stature” (9%), “cleft palate” (8%), “immunodeficiency” (8%), “autism” (8%), “failure to thrive” (8%), “abnormality of the cerebral white matter” (8%), “delayed speech and language development” (7%), and “cryptorchidism” (7%) (<xref ref-type="fig" rid="MCS003756JIF1">Fig. 1</xref>B). The majority of patients had negative chromosomal microarray (CMA) results and many had single gene or gene panel testing that was uninformative. Three patients with positive CMA results were referred for WES because of concern for a second genetic disorder.</p><fig id="MCS003756JIF1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Descriptive statistics of the 106 clinical WES cases. The 106 clinical cases were referred from nine divisions (<italic>A</italic>). Patients presented with a range of phenotypes. The most common 12 clinical phenotypes are listed (<italic>B</italic>).</p></caption><graphic xlink:href="MCS003756Ji_F1"></graphic></fig></sec><sec id="s2b"><title>WES Molecular Diagnoses and Findings</title><p>A total of 40 molecular diagnoses were obtained in 38 of 106 patients, achieving an overall diagnostic rate of 36%. The diagnostic rate was 28% (11/40) for singleton-WES and 41% (27/66) for duo-, quad-, and trio-WES, respectively. The diagnostic yield for trio-WES is equal to or higher than 12 of the 13 exome studies of pediatric patient populations (<xref ref-type="bibr" rid="MCS003756JIC6">Dragojlovic et al. 2018</xref>). Of note, 42% (18/43) of patients between 1 and 5 years old had pathogenic or likely pathogenic diagnostic findings, higher than the diagnostic rate of 27% (6/22) for patients younger than 12 mo, and 34% (14/41) for patients between 6 and 22 yr (<xref ref-type="table" rid="MCS003756JITB1">Table 1</xref>; <ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Table 1</ext-link>). Further prospective studies with a significantly larger patient population are required to draw any conclusions from this interesting observation.</p><table-wrap id="MCS003756JITB1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Whole-exome sequencing results in 38 patients with molecular diagnoses and in four patients with likely pathogenic findings</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Study ID</th><th align="center" colspan="1" rowspan="1">Study type</th><th align="center" colspan="1" rowspan="1">Gender</th><th align="center" colspan="1" rowspan="1">Age</th><th align="center" colspan="1" rowspan="1">Gene</th><th align="center" colspan="1" rowspan="1">Zygosity</th><th align="center" colspan="1" rowspan="1">Transcript ID</th><th align="center" colspan="1" rowspan="1">DNA change</th><th align="center" colspan="1" rowspan="1">Protein change</th><th align="center" colspan="1" rowspan="1">Classification</th><th align="center" colspan="1" rowspan="1">Inherited from</th><th align="center" colspan="1" rowspan="1">Inheritance</th><th align="center" colspan="1" rowspan="1">MIM ID</th><th align="center" colspan="1" rowspan="1">Exomiser rank</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">4 yo</td><td colspan="1" rowspan="1"><italic>GRIN1</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_007327.3</td><td colspan="1" rowspan="1">c.2531G &gt; T</td><td colspan="1" rowspan="1">p.Arg844Leu</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">614254</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">4 yo</td><td colspan="1" rowspan="1"><italic>STAT1</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_007315.3</td><td colspan="1" rowspan="1">c.1154C &gt; T</td><td colspan="1" rowspan="1">p.Thr385Met</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">614162</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="2">15</td><td colspan="1" rowspan="2">Trio</td><td colspan="1" rowspan="2">Male</td><td colspan="1" rowspan="2">8 yo</td><td colspan="1" rowspan="1"><italic>CREBBP</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_004380.2</td><td colspan="1" rowspan="1">c.5603G &gt; A</td><td colspan="1" rowspan="1">p.Arg1868Gln</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">180849</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"><italic>COL5A2</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_000393.3</td><td colspan="1" rowspan="1">c.1842G &gt; A</td><td colspan="1" rowspan="1">p.Met614Ile</td><td colspan="1" rowspan="1">VUS</td><td colspan="1" rowspan="1">Mother</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Not ranked</td></tr><tr><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">Singleton</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">9 yo</td><td colspan="1" rowspan="1"><italic>CLN6</italic></td><td colspan="1" rowspan="1">Homo</td><td colspan="1" rowspan="1">NM_017882.2</td><td colspan="1" rowspan="1">c.395_396<break></break>delCT</td><td colspan="1" rowspan="1">p.Ser132Cysfs*18</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">Mother and father</td><td colspan="1" rowspan="1">AR</td><td colspan="1" rowspan="1">601780</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="2">34</td><td colspan="1" rowspan="2">Trio</td><td colspan="1" rowspan="2">Female</td><td colspan="1" rowspan="2">7 yo</td><td colspan="1" rowspan="1"><italic>TMCO1</italic></td><td colspan="1" rowspan="1">Homo</td><td colspan="1" rowspan="1">NM_019026.4</td><td colspan="1" rowspan="1">c.646_647<break></break>delGC</td><td colspan="1" rowspan="1">p.Ala216Profs*53</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">Mother and father</td><td colspan="1" rowspan="1">AR</td><td colspan="1" rowspan="1">213980</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"><italic>DNAH11</italic></td><td colspan="1" rowspan="1">Homo</td><td colspan="1" rowspan="1">NM_001277115.1</td><td colspan="1" rowspan="1">c.10472G &gt; A</td><td colspan="1" rowspan="1">p.Arg3491His</td><td colspan="1" rowspan="1">VUS</td><td colspan="1" rowspan="1">Mother and father</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">611884</td><td colspan="1" rowspan="1">14</td></tr><tr><td colspan="1" rowspan="2">43</td><td colspan="1" rowspan="2">Trio</td><td colspan="1" rowspan="2">Female</td><td colspan="1" rowspan="2">5 yo</td><td colspan="1" rowspan="1"><italic>STAT1</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_007315.3</td><td colspan="1" rowspan="1">c.1154C &gt; T</td><td colspan="1" rowspan="1">p.Thr385Met</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">614162</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"><italic>SCNN1A</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_001159576.1</td><td colspan="1" rowspan="1">c.1604G &gt; A</td><td colspan="1" rowspan="1">p.Arg535Gln</td><td colspan="1" rowspan="1">VUS</td><td colspan="1" rowspan="1">Father</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Not ranked</td></tr><tr><td colspan="1" rowspan="1">47</td><td colspan="1" rowspan="1">Quad</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">7 yo</td><td colspan="1" rowspan="1"><italic>TMCO1</italic></td><td colspan="1" rowspan="1">Homo</td><td colspan="1" rowspan="1">NM_019026.4</td><td colspan="1" rowspan="1">c.616C &gt; T</td><td colspan="1" rowspan="1">p.Arg206*</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">Mother and father</td><td colspan="1" rowspan="1">AR</td><td colspan="1" rowspan="1">213980</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">52</td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">2 yo</td><td colspan="1" rowspan="1"><italic>FOXP3</italic></td><td colspan="1" rowspan="1">Hemi</td><td colspan="1" rowspan="1">NM_014009.3</td><td colspan="1" rowspan="1">c.1190G &gt; A</td><td colspan="1" rowspan="1">p.Arg397Gln</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">Mother</td><td colspan="1" rowspan="1">XLR</td><td colspan="1" rowspan="1">304790</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">55</td><td colspan="1" rowspan="1">Duo</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">6 yo</td><td colspan="1" rowspan="1"><italic>STAT1</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_007315.3</td><td colspan="1" rowspan="1">c.821G &gt; A</td><td colspan="1" rowspan="1">p.Arg274Gln</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">Nonmaternal</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">614162</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">61</td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">2 yo</td><td colspan="1" rowspan="1"><italic>SCN1A</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_001202435.1</td><td colspan="1" rowspan="1">c.3327dupC</td><td colspan="1" rowspan="1">p.Ser1110Glnfs*14</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">607208</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">65</td><td colspan="1" rowspan="1">Duo+ sibling</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">17 yo</td><td colspan="1" rowspan="1"><italic>FKBP10</italic></td><td colspan="1" rowspan="1">Homo</td><td colspan="1" rowspan="1">NM_021939.3</td><td colspan="1" rowspan="1">c.831dupC</td><td colspan="1" rowspan="1">p.Gly278Argfs*95</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">Mother and father</td><td colspan="1" rowspan="1">AR</td><td colspan="1" rowspan="1">259450; 610968</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">72</td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">22 yo</td><td colspan="1" rowspan="1"><italic>ATRX</italic></td><td colspan="1" rowspan="1">Hemi</td><td colspan="1" rowspan="1">NM_000489.4</td><td colspan="1" rowspan="1">c.7156C &gt; T</td><td colspan="1" rowspan="1">p.Arg2386*</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">Mother (het)</td><td colspan="1" rowspan="1">XLR</td><td colspan="1" rowspan="1">309580</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">82</td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">20 mo</td><td colspan="1" rowspan="1"><italic>ALG13</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_001099922.2</td><td colspan="1" rowspan="1">c.50T &gt; A</td><td colspan="1" rowspan="1">p.Ile17Asn</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">XLD</td><td colspan="1" rowspan="1">300884</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="3">83</td><td colspan="1" rowspan="3">Trio</td><td colspan="1" rowspan="3">Female</td><td colspan="1" rowspan="3">19 mo</td><td colspan="1" rowspan="1"><italic>CHN1</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_001822.5</td><td colspan="1" rowspan="1">c.667G &gt; A</td><td colspan="1" rowspan="1">p.Ala223Thr</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">Father</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">604356</td><td colspan="1" rowspan="1">Not ranked</td></tr><tr><td colspan="1" rowspan="1"><italic>WFS1</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_006005.3</td><td colspan="1" rowspan="1">c.1999C &gt; T</td><td colspan="1" rowspan="1">p.Gln667*</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">Mother</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">600965</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1"><italic>KIF1A</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_001244008.1</td><td colspan="1" rowspan="1">c.3052C &gt; T</td><td colspan="1" rowspan="1">p.His1018Tyr</td><td colspan="1" rowspan="1">VUS</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="2">85</td><td colspan="1" rowspan="2">Duo</td><td colspan="1" rowspan="2">Female</td><td colspan="1" rowspan="2">2 yo</td><td colspan="1" rowspan="1"><italic>QARS</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_005051.2</td><td colspan="1" rowspan="1">c.1430A &gt; G</td><td colspan="1" rowspan="1">p.Tyr477Cys</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">Nonmaternal</td><td colspan="1" rowspan="1">AR</td><td colspan="1" rowspan="1">615760</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"><italic>QARS</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_005051.2</td><td colspan="1" rowspan="1">c.1132C &gt; T</td><td colspan="1" rowspan="1">p.Arg378Cys</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">Mother</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">615760</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">88</td><td colspan="1" rowspan="1">Singleton</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">9 yo</td><td colspan="1" rowspan="1"><italic>PTEN</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_000314.5</td><td colspan="1" rowspan="1">c.203A &gt; G</td><td colspan="1" rowspan="1">p.Tyr68Cys</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">158350; 605309</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">94<sup>b</sup></td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">3 yo</td><td colspan="1" rowspan="1"><italic>PLAA</italic></td><td colspan="1" rowspan="1">Homo</td><td colspan="1" rowspan="1">NM_001031689.2</td><td colspan="1" rowspan="1">c.1487-1G &gt; A</td><td colspan="1" rowspan="1">p.?</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">Mother and father</td><td colspan="1" rowspan="1">AR</td><td colspan="1" rowspan="1">617527</td><td colspan="1" rowspan="1">10</td></tr><tr><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">22 mo</td><td colspan="1" rowspan="1"><italic>PACS1</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_018026.3</td><td colspan="1" rowspan="1">c.607C &gt; T</td><td colspan="1" rowspan="1">p.Arg203Trp</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">615009</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">104</td><td colspan="1" rowspan="1">Singleton</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">5 wo</td><td colspan="1" rowspan="1"><italic>MTM1</italic></td><td colspan="1" rowspan="1">Hemi</td><td colspan="1" rowspan="1">NM_000252.2</td><td colspan="1" rowspan="1">c.1262G &gt; T</td><td colspan="1" rowspan="1">p.Arg421Leu</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">XLR</td><td colspan="1" rowspan="1">310400</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="2">109</td><td colspan="1" rowspan="2">Singleton</td><td colspan="1" rowspan="2">Male</td><td colspan="1" rowspan="2">2 mo</td><td colspan="1" rowspan="1"><italic>SFTPC</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_001172357.1</td><td colspan="1" rowspan="1">c.163C &gt; T</td><td colspan="1" rowspan="1">p.Leu55Phe</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">Mother</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">610913</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1"><italic>DES</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_001927.3</td><td colspan="1" rowspan="1">c.407T &gt; A</td><td colspan="1" rowspan="1">p.Leu136His</td><td colspan="1" rowspan="1">VUS</td><td colspan="1" rowspan="1">Father</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">115</td><td colspan="1" rowspan="1">Singleton</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">2 wo</td><td colspan="1" rowspan="1"><italic>ABCA3</italic></td><td colspan="1" rowspan="1">Homo</td><td colspan="1" rowspan="1">NM_001089.2</td><td colspan="1" rowspan="1">c.2279T &gt; G</td><td colspan="1" rowspan="1">p.Met760Arg</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1">AR</td><td colspan="1" rowspan="1">610921</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="2">126</td><td colspan="1" rowspan="2">Singleton</td><td colspan="1" rowspan="2">Male</td><td colspan="1" rowspan="2">8 yo</td><td colspan="1" rowspan="1"><italic>NSD1</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_022455.4</td><td colspan="1" rowspan="1">c.3839G &gt; A</td><td colspan="1" rowspan="1">p.Trp1280*</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">117550</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"><italic>FGF14</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_004115.3</td><td colspan="1" rowspan="1">c.486dup</td><td colspan="1" rowspan="1">p.Arg163Glnfs*7</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">Father</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">609307</td><td colspan="1" rowspan="1">27</td></tr><tr><td colspan="1" rowspan="1">127<sup>b</sup></td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">5 yo</td><td colspan="1" rowspan="1"><italic>ANK2</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_001148.4</td><td colspan="1" rowspan="1">c.1417C &gt; T</td><td colspan="1" rowspan="1">p.Arg473*</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="2">130</td><td colspan="1" rowspan="2">Trio</td><td colspan="1" rowspan="2">Male</td><td colspan="1" rowspan="2">1 yo</td><td colspan="1" rowspan="1"><italic>SZT2</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_015284.3</td><td colspan="1" rowspan="1">c.4854-2A &gt; G</td><td colspan="1" rowspan="1">p.?</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">Mother</td><td colspan="1" rowspan="1">AR</td><td colspan="1" rowspan="1">615476</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1"><italic>SZT2</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_015284.3</td><td colspan="1" rowspan="1">c.5949_5951<break></break>delTGT</td><td colspan="1" rowspan="1">p.Val1984del</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">Father</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">615476</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="2">132</td><td colspan="1" rowspan="2">Trio</td><td colspan="1" rowspan="2">Male</td><td colspan="1" rowspan="2">15 yo</td><td colspan="1" rowspan="1"><italic>DNAJC21</italic></td><td colspan="1" rowspan="1">Homo</td><td colspan="1" rowspan="1">NM_194283.3</td><td colspan="1" rowspan="1">c.544C &gt; T</td><td colspan="1" rowspan="1">p.Arg182*</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">Mother and father</td><td colspan="1" rowspan="1">AR</td><td colspan="1" rowspan="1">617052</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1"><italic>TP53</italic><sup><italic>a</italic></sup></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_000546.5</td><td colspan="1" rowspan="1">c.742C &gt; T</td><td colspan="1" rowspan="1">p.Arg248Trp</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">133</td><td colspan="1" rowspan="1">Singleton</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">3 yo</td><td colspan="1" rowspan="1"><italic>COL17A1</italic></td><td colspan="1" rowspan="1">Homo</td><td colspan="1" rowspan="1">NM_000494.3</td><td colspan="1" rowspan="1">c.4145_4148<break></break>delAGAG</td><td colspan="1" rowspan="1">p.Glu1382Alafs*40</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">Likely mother and father</td><td colspan="1" rowspan="1">AR</td><td colspan="1" rowspan="1">226650</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">135<sup>b</sup></td><td colspan="1" rowspan="1">Singleton</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">14 yo</td><td colspan="1" rowspan="1"><italic>RAD50</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_005732.3</td><td colspan="1" rowspan="1">c.2165dupA</td><td colspan="1" rowspan="1">p.Glu723Glyfs*5</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">36</td></tr><tr><td colspan="1" rowspan="2">144</td><td colspan="1" rowspan="2">Trio</td><td colspan="1" rowspan="2">Male</td><td colspan="1" rowspan="2">4 yo</td><td colspan="1" rowspan="1"><italic>SETD2</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_014159.6</td><td colspan="1" rowspan="1">c.5152G &gt; A</td><td colspan="1" rowspan="1">p.Glu1718Lys</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">616831</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"><italic>SPAST</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_014946.3</td><td colspan="1" rowspan="1">c.489A &gt; G</td><td colspan="1" rowspan="1">p.Ile163Met</td><td colspan="1" rowspan="1">VUS</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">182601</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1">156</td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">5 yo</td><td colspan="1" rowspan="1"><italic>BPTF</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_004459.6</td><td colspan="1" rowspan="1">c.5715_5716<break></break>delAG</td><td colspan="1" rowspan="1">p.Val1906Glufs*15</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">617755</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1">163</td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">6 yo</td><td colspan="1" rowspan="1"><italic>RPS26</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_001029.3</td><td colspan="1" rowspan="1">c.1A &gt; C</td><td colspan="1" rowspan="1">p.Met1?</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">613309</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">165</td><td colspan="1" rowspan="1">Singleton</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">10 yo</td><td colspan="1" rowspan="1"><italic>BCL11A</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_022893.3</td><td colspan="1" rowspan="1">c.152G &gt; C</td><td colspan="1" rowspan="1">p.Cys51Ser</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">617101</td><td colspan="1" rowspan="1">52<sup>c</sup></td></tr><tr><td colspan="1" rowspan="2">167</td><td colspan="1" rowspan="2">Trio</td><td colspan="1" rowspan="2">Female</td><td colspan="1" rowspan="2">3 yo</td><td colspan="1" rowspan="1"><italic>SPTA1</italic></td><td colspan="1" rowspan="1">Homo</td><td colspan="1" rowspan="1">NM_003126.2</td><td colspan="1" rowspan="1">c.7132C &gt; T</td><td colspan="1" rowspan="1">p.Gln2378*</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">Mother and father</td><td colspan="1" rowspan="1">AR</td><td colspan="1" rowspan="1">266140; 270970</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"><italic>G6PD</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_000402.4</td><td colspan="1" rowspan="1">c.653C &gt; T</td><td colspan="1" rowspan="1">p.Ser218Phe</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">Mother (het)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">134700; 300908; 611162</td><td colspan="1" rowspan="1">Not ranked</td></tr><tr><td colspan="1" rowspan="1">186</td><td colspan="1" rowspan="1">Singleton</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">D.N.</td><td colspan="1" rowspan="1"><italic>PKHD1</italic></td><td colspan="1" rowspan="1">Homo</td><td colspan="1" rowspan="1">NM_138694.3</td><td colspan="1" rowspan="1">c.1480C &gt; T</td><td colspan="1" rowspan="1">p.Arg494*</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">Likely mother and father</td><td colspan="1" rowspan="1">AR</td><td colspan="1" rowspan="1">263200</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">193</td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">2 yo</td><td colspan="1" rowspan="1"><italic>EIF2B5</italic></td><td colspan="1" rowspan="1">Homo</td><td colspan="1" rowspan="1">NM_003907.2</td><td colspan="1" rowspan="1">c.943C &gt; T</td><td colspan="1" rowspan="1">p.Arg315Cys</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">Mother and father</td><td colspan="1" rowspan="1">AR</td><td colspan="1" rowspan="1">603896</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">194<sup>b</sup></td><td colspan="1" rowspan="1">Singleton</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">22 do</td><td colspan="1" rowspan="1"><italic>FOXN1</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_003593.2</td><td colspan="1" rowspan="1">c.1247delC</td><td colspan="1" rowspan="1">p.Pro416Glnfs*134</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">601705</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">198</td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">34 mo</td><td colspan="1" rowspan="1"><italic>ARID1B</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_020732.3</td><td colspan="1" rowspan="1">c.5968C &gt; T</td><td colspan="1" rowspan="1">p.Arg1990*</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">135900</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="3">200</td><td colspan="1" rowspan="3">Singleton</td><td colspan="1" rowspan="3">Female</td><td colspan="1" rowspan="3">6 yo</td><td colspan="1" rowspan="1"><italic>PGAP3</italic></td><td colspan="1" rowspan="1">Homo</td><td colspan="1" rowspan="1">NM_033419.4</td><td colspan="1" rowspan="1">c.851A &gt; G</td><td colspan="1" rowspan="1">p.His284Arg</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">Likely mother and father</td><td colspan="1" rowspan="1">AR</td><td colspan="1" rowspan="1">615716</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"><italic>MYO15A</italic></td><td colspan="1" rowspan="1">Homo</td><td colspan="1" rowspan="1">NM_016239.3</td><td colspan="1" rowspan="1">c.1454T &gt; C</td><td colspan="1" rowspan="1">p.Val485Ala</td><td colspan="1" rowspan="1">VUS</td><td colspan="1" rowspan="1">Likely mother and father</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">35</td></tr><tr><td colspan="1" rowspan="1"><italic>DEPDC5</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_001242896.1</td><td colspan="1" rowspan="1">c.2785G &gt; A</td><td colspan="1" rowspan="1">p.Gly929Ser</td><td colspan="1" rowspan="1">VUS</td><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">56</td></tr><tr><td colspan="1" rowspan="1">205</td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">9 mo</td><td colspan="1" rowspan="1"><italic>RAC2</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_002872.3</td><td colspan="1" rowspan="1">c.184G &gt; A</td><td colspan="1" rowspan="1">p.Glu62Lys</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">608203</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">215</td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">3 yo</td><td colspan="1" rowspan="1"><italic>PPP2R1A</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_014225.5</td><td colspan="1" rowspan="1">c.773G &gt; A</td><td colspan="1" rowspan="1">p.Arg258His</td><td colspan="1" rowspan="1">Pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">616362</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">216</td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">3 yo</td><td colspan="1" rowspan="1"><italic>SLC9A6</italic></td><td colspan="1" rowspan="1">Hemi</td><td colspan="1" rowspan="1">NM_001042537.1</td><td colspan="1" rowspan="1">c.1728-19_1728-3del</td><td colspan="1" rowspan="1">p.?</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">XLD</td><td colspan="1" rowspan="1">300243</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">219</td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">14 yo</td><td colspan="1" rowspan="1"><italic>FAM111B</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_198947.3</td><td colspan="1" rowspan="1">c.1462delT</td><td colspan="1" rowspan="1">p.Cys488Valfs*21</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">AD</td><td colspan="1" rowspan="1">615704</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="2">224</td><td colspan="1" rowspan="2">Singleton</td><td colspan="1" rowspan="2">Male</td><td colspan="1" rowspan="2">11 mo</td><td colspan="1" rowspan="1"><italic>XIAP</italic></td><td colspan="1" rowspan="1">Hemi</td><td colspan="1" rowspan="1">NM_001167.3</td><td colspan="1" rowspan="1">c.562G &gt; A</td><td colspan="1" rowspan="1">p.Gly188Arg</td><td colspan="1" rowspan="1">Likely pathogenic</td><td colspan="1" rowspan="1">Mother (het)</td><td colspan="1" rowspan="1">XLR</td><td colspan="1" rowspan="1">300635</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"><italic>GATA2</italic></td><td colspan="1" rowspan="1">Het</td><td colspan="1" rowspan="1">NM_001145661.1</td><td colspan="1" rowspan="1">c.445G &gt; A</td><td colspan="1" rowspan="1">p.Gly149Arg</td><td colspan="1" rowspan="1">VUS</td><td colspan="1" rowspan="1">Mother</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">3</td></tr></tbody></table><table-wrap-foot><fn><p>(yo) Year old, (mo) month old, (wo) week old, (do) day old, (D.N.) deceased newborn, (Het) heterozygous, (Homo) homozygous, (Hemi) hemizygous.</p></fn><fn><p><sup>a</sup>Potentially somatic alteration.</p></fn><fn><p><sup>b</sup>Patients with potential diagnoses.</p></fn><fn><p><sup>c</sup>52nd place using Exomiser version 7.2.1 at the time of initial analysis in 2016; 1st place using Exomiser version 10.1.1 in the end of this study.</p></fn></table-wrap-foot></table-wrap><p>Thirty-eight patients received a total of 40 molecular diagnoses, of which 52.5% (21/40) were autosomal dominant (AD) diseases, 32.5% (13/40) were autosomal recessive (AR) diseases, and 15% (6/40) were X-linked diseases (<xref ref-type="table" rid="MCS003756JITB1">Tables 1</xref> and <xref ref-type="table" rid="MCS003756JITB2">2</xref>). De novo variants accounted for 67% (14/21) of AD conditions. Of the six patients with X-linked diseases, three had de novo variants (<xref ref-type="table" rid="MCS003756JITB1">Tables 1</xref>, <xref ref-type="table" rid="MCS003756JITB2">2</xref>; <ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Table 1</ext-link>). Two patients (Patient 83 and 126) had dual molecular findings (<xref ref-type="table" rid="MCS003756JITB1">Table 1</xref>). Preliminary results were returned to the ordering physician in as few as 3 d and within 1 wk for 32% (12/38) of patients with positive findings, most of whom were in the neonatal intensive care unit. The timely delivery of the molecular diagnoses had an impact on the clinical management of these patients (see below). Follow-up family segregation analyses, particularly for singleton-WES cases, were helpful in further clarifying the variants’ pathogenicity. For example, the pathogenic variant classification was further supported for Patients 104 and 126 in whom the variant was confirmed to be de novo in the proband using targeted Sanger sequencing on both parents. In contrast, we reclassified a hemizygous <italic>BCORL1</italic> variant from variant of uncertain significance (VUS) to likely benign (Patient 69) because of its cosegregation in two other unaffected male siblings (WES study IDs: 148 and 177) (<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Table 1</ext-link>).</p><table-wrap id="MCS003756JITB2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Modes of inheritance observed across 40 molecular diagnoses in 38 patients</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Mode of inheritance</th><th align="center" colspan="1" rowspan="1">Number of diagnoses</th><th align="center" colspan="1" rowspan="1">Percent of diagnosis</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><bold>Autosomal dominant</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"><bold>21 (52.5%)</bold></td></tr><tr><td colspan="1" rowspan="1"> De novo</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Inherited from one of the parents</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Inheritance unknown</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Nonmaternal</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Autosomal recessive</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"><bold>13 (32.5%)</bold></td></tr><tr><td colspan="1" rowspan="1"> Homozygous</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Compound heterozygous</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>X-linked recessive and dominant</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"><bold>6 (15%)</bold></td></tr><tr><td colspan="1" rowspan="1"> De novo</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Hemizygous inherited from the heterozygous mother</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1"></td></tr></tbody></table></table-wrap><p>Interestingly, eight patients had a finding in genes associated with cancer predisposition (<xref ref-type="table" rid="MCS003756JITB3">Table 3</xref>). These included pathogenic variants in <italic>DNAJC21, RAD50</italic>, and <italic>ATRX</italic> identified in patients with cancer, a <italic>PMS2</italic> nonsense variant detected in a patient with a family history of colon cancer, and <italic>MEN1</italic>, <italic>RET</italic>, <italic>BRCA2</italic>, and <italic>CHEK2</italic> variants in patients without a clinical or family history of cancer (<xref ref-type="table" rid="MCS003756JITB3">Table 3</xref>). Notably, we were the first to report <italic>ATRX</italic> as a potential cancer predisposition gene for osteosarcoma using our WES platform (Patient 72) (<xref ref-type="bibr" rid="MCS003756JIC15">Ji et al. 2017</xref>). The association between a germline pathogenic <italic>ATRX</italic> variant and osteosarcoma was subsequently reported (<xref ref-type="bibr" rid="MCS003756JIC28">Smolle et al. 2017</xref>; <xref ref-type="bibr" rid="MCS003756JIC23">Masliah-Planchon et al. 2018</xref>).</p><table-wrap id="MCS003756JITB3" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Pathogenic and likely pathogenic variants identified in genes associated with cancer predisposition</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Exome study ID</th><th align="center" colspan="1" rowspan="1">Gender</th><th align="center" colspan="1" rowspan="1">Age</th><th align="center" colspan="1" rowspan="1">Clinical phenotypes</th><th align="center" colspan="1" rowspan="1">Gene</th><th align="center" colspan="1" rowspan="1">Zygosity</th><th align="center" colspan="1" rowspan="1">Variant identified</th><th align="center" colspan="1" rowspan="1">Inherited from</th><th align="center" colspan="1" rowspan="1">Referring source</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">132</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">15 yr</td><td colspan="1" rowspan="1">Short stature, webbed neck, white patch on the tongue, intellectual disability, acute myeloid leukemia, pancytopenia, and pectus excavatum</td><td colspan="1" rowspan="1"><italic>DNAJC21</italic></td><td colspan="1" rowspan="1">Homozygous</td><td colspan="1" rowspan="1">NM_194283.3: c.544C &gt; T (p.Arg182*)</td><td colspan="1" rowspan="1">Mother and father</td><td colspan="1" rowspan="1">Heme/Oncology</td></tr><tr><td colspan="1" rowspan="1">135</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">14 yr</td><td colspan="1" rowspan="1">History of unilateral retinoblastoma and pilocytic astrocytoma, mild ataxia, brachydactyly, dental malocclusion, high, narrow palate, pigmented freckles and right shoulder granular tumor</td><td colspan="1" rowspan="1"><italic>RAD50</italic></td><td colspan="1" rowspan="1">Heterozygous</td><td colspan="1" rowspan="1">NM_005732.3: c.2165dupA (p.Glu723Glyfs*5)</td><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1">Genetics</td></tr><tr><td colspan="1" rowspan="1">72</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">22 yr</td><td colspan="1" rowspan="1">Dysmorphic features, microcephaly, severe intellectual disability (nonverbal), mild anemia, cryptorchidism and osteosarcoma</td><td colspan="1" rowspan="1"><italic>ATRX</italic></td><td colspan="1" rowspan="1">Hemizygous</td><td colspan="1" rowspan="1">NM_000489.4: c.7156C &gt; T (p.Arg2386*)</td><td colspan="1" rowspan="1">Mother (heterozygous)</td><td colspan="1" rowspan="1">Heme /Oncology</td></tr><tr><td colspan="1" rowspan="1">174</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">2 wk</td><td colspan="1" rowspan="1">Respiratory insufficiency and pulmonary hypertension. Maternal family history of colon cancer</td><td colspan="1" rowspan="1"><italic>PMS2</italic></td><td colspan="1" rowspan="1">Heterozygous</td><td colspan="1" rowspan="1">NM_000535.5: c.1927C &gt; T (p.Gln643*)</td><td colspan="1" rowspan="1">Mother</td><td colspan="1" rowspan="1">Neonatology/Pulmonology</td></tr><tr><td colspan="1" rowspan="1">193</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">2 yr</td><td colspan="1" rowspan="1">Developmental delay, leukodystrophy, vanishing whiter matter and dystonia</td><td colspan="1" rowspan="1"><italic>MEN1</italic></td><td colspan="1" rowspan="1">Heterozygous</td><td colspan="1" rowspan="1">NM_130803.2:c.1633C &gt; T (p.Pro545Ser)</td><td colspan="1" rowspan="1">Mother</td><td colspan="1" rowspan="1">Neurology</td></tr><tr><td colspan="1" rowspan="1">127</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">5 yr</td><td colspan="1" rowspan="1">Microcephaly, global developmental delay, delayed speech and language development, aggressive behavior, seizures, epileptic spasms, infantile spasms, hyperammonemia, and intellectual disability</td><td colspan="1" rowspan="1"><italic>RET</italic></td><td colspan="1" rowspan="1">Heterozygous</td><td colspan="1" rowspan="1">NM_020975.4: c.1907C &gt; T (p.Thr636Met)</td><td colspan="1" rowspan="1">Father</td><td colspan="1" rowspan="1">Genetics</td></tr><tr><td colspan="1" rowspan="1">87</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">16 yr</td><td colspan="1" rowspan="1">Ectopic ossification, muscle weakness, nephrolithiasis, asthma, headache, migraine, obesity, short attention span, and striae distensae</td><td colspan="1" rowspan="1"><italic>BRCA2</italic></td><td colspan="1" rowspan="1">Heterozygous</td><td colspan="1" rowspan="1">NM_000059.3:c.4936_4939delGAAA (p.Glu1646Glnfs*23)</td><td colspan="1" rowspan="1">Father</td><td colspan="1" rowspan="1">Endocrinology</td></tr><tr><td colspan="1" rowspan="1">110</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">20 mo</td><td colspan="1" rowspan="1">Colitis, hematochezia, inflammation of the large intestine, and thrombocytopenia</td><td colspan="1" rowspan="1"><italic>CHEK2</italic></td><td colspan="1" rowspan="1">Heterozygous</td><td colspan="1" rowspan="1">NM_007194.3: c.1100delC (p.Thr367Metfs*15)</td><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1">Immunology</td></tr></tbody></table></table-wrap></sec><sec id="s2c"><title>Exomiser Results for WES Clinical Cases and Identification of Novel Candidate Variants</title><p>For the 43 reported pathogenic and likely pathogenic variants in 38 clinical cases, Exomiser ranked 72.1% (31/43) variants as the top candidate in 30 cases, 20.9% (9/43) in second to sixth place in seven cases, and 6.9% (3/43) at 27th place or not ranked in three cases (<xref ref-type="table" rid="MCS003756JITB1">Table 1</xref>). Together, 93% (40/43) of pathogenic or likely pathogenic variants were ranked in the top 6 by Exomiser. The Exomiser rank for sequencing variants identified in the clinical cases is shown in <xref ref-type="table" rid="MCS003756JITB1">Table 1</xref>.</p><sec id="s2c1"><title>Updated Molecular Diagnoses Using Recent Gene–Disease Associations</title><p>The highest rank by Exomiser initially for candidate variants in <italic>BPTF</italic>, <italic>DNAJC21</italic>, <italic>PLAA</italic>, and <italic>BCL11A</italic> were the second place, third place, 10th place, and the 52nd place for Patient 156, 132, 94, and 165, respectively (<xref ref-type="table" rid="MCS003756JITB4">Table 4</xref>). There were no published disease associations with these genes when WES was initially performed, and therefore according to ACMG guidelines, they should not have been clinically reported. However, the nature of the variants indicated that these variants were potentially disease-causing. These four genes were later shown to have clear disease associations (<xref ref-type="bibr" rid="MCS003756JIC5">Dias et al. 2016</xref>; <xref ref-type="bibr" rid="MCS003756JIC31">Tummala et al. 2016</xref>; <xref ref-type="bibr" rid="MCS003756JIC12">Hall et al. 2017</xref>; <xref ref-type="bibr" rid="MCS003756JIC29">Stankiewicz et al. 2017</xref>). Stankiewicz et al. first described the gene disease association for <italic>BPTF</italic>, an AD neurodevelopmental disorder with dysmorphic facies and distal limb anomalies (MIM: 617755) (<xref ref-type="bibr" rid="MCS003756JIC29">Stankiewicz et al. 2017</xref>), which largely overlaps with our patients’ clinical presentation (Patient 156). This patient had a de novo truncating variant in <italic>BPTF.</italic> A homozygous canonical splice-site variant in <italic>PLAA</italic> was identified in a family (case 94) with two affected children suspected to have an AR disease. The <italic>PLAA</italic> gene was very recently shown to be associated with an AR neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies by Falik Zaccai et al. and Hall et al., subsequent to the original clinical study for this family (<xref ref-type="bibr" rid="MCS003756JIC7">Falik Zaccai et al. 2017</xref>; <xref ref-type="bibr" rid="MCS003756JIC12">Hall et al. 2017</xref>). Similarly, since the time of the original analysis for Patient 132 new studies have been published that described an AR bone marrow failure syndrome (MIM: 617052) caused by germline biallelic pathogenic variants in <italic>DNAJC21</italic> (<xref ref-type="bibr" rid="MCS003756JIC31">Tummala et al. 2016</xref>; <xref ref-type="bibr" rid="MCS003756JIC4">Dhanraj et al. 2017</xref>; <xref ref-type="bibr" rid="MCS003756JIC2">Bluteau et al. 2018</xref>). The disorder is characterized by onset of pancytopenia in early childhood. Patients may have additional variable nonspecific abnormalities, including poor growth, microcephaly, and skin anomalies (<xref ref-type="bibr" rid="MCS003756JIC31">Tummala et al. 2016</xref>; <xref ref-type="bibr" rid="MCS003756JIC4">Dhanraj et al. 2017</xref>), which also fits the clinical presentation of our patient. The proband had a homozygous nonsense variant in <italic>DNAJC21</italic> inherited in an AR manner from both parents who were heterozygous for this variant. Patient 165 had a novel <italic>BCL11A</italic> missense variant identified in a highly conserved region of the gene where missense variants are depleted in the general population (ExAC missense constraint <italic>z</italic>-score = 5.52). Since the time of initial exome analysis, new publications have described the AD Dias–Logan syndrome (MIM: 617101), caused by de novo heterozygous pathogenic variants in the <italic>BCL11A</italic> gene (<xref ref-type="bibr" rid="MCS003756JIC5">Dias et al. 2016</xref>). The disorder is characterized by delayed psychomotor development, intellectual disability, variable dysmorphic features, including microcephaly, downslanting palpebral fissures, strabismus, and external ear abnormalities, as well as asymptomatic persistence of fetal hemoglobin, which overlaps the patient's clinical presentation. Revised clinical reports were therefore issued that included the novel pathogenic or likely pathogenic variants for these patients. Our findings enrich the phenotypic characteristics of these newly established syndromes.</p><table-wrap id="MCS003756JITB4" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Potential molecular diagnosis at the time of WES analysis</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Study ID</th><th align="center" colspan="1" rowspan="1">Study type</th><th align="center" colspan="1" rowspan="1">Gender</th><th align="center" colspan="1" rowspan="1">Gene</th><th align="center" colspan="1" rowspan="1">Chromosomal position (GRCh37)</th><th align="center" colspan="1" rowspan="1">HGVS DNA reference</th><th align="center" colspan="1" rowspan="1">HGVS protein reference</th><th align="center" colspan="1" rowspan="1">Variant type</th><th align="center" colspan="1" rowspan="1">Predicted effect</th><th align="center" colspan="1" rowspan="1">dbSNP/dbVar ID</th><th align="center" colspan="1" rowspan="1">Genotype</th><th align="center" colspan="1" rowspan="1">Parent of origin</th><th align="center" colspan="1" rowspan="1">Exomiser rank</th><th align="center" colspan="1" rowspan="1">Supporting references</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">156<sup>a</sup></td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1"><italic>BPTF</italic></td><td colspan="1" rowspan="1">Chr 17:65,914,
863_65,914,864</td><td colspan="1" rowspan="1">NM_004459.6: c.5715_5716delAG</td><td colspan="1" rowspan="1">p.Val1906Glufs*15</td><td colspan="1" rowspan="1">Deletion</td><td colspan="1" rowspan="1">Frameshift</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">Heterozygous</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1"><xref ref-type="bibr" rid="MCS003756JIC29">Stankiewicz et al. 2017</xref></td></tr><tr><td colspan="1" rowspan="1">132<sup>a</sup></td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1"><italic>DNAJC21</italic></td><td colspan="1" rowspan="1">Chr 5:34,937,536</td><td colspan="1" rowspan="1">NM_194283.3: c.544C&gt;T</td><td colspan="1" rowspan="1">p.Arg182*</td><td colspan="1" rowspan="1">Substitution</td><td colspan="1" rowspan="1">Nonsense</td><td colspan="1" rowspan="1">rs771063992</td><td colspan="1" rowspan="1">Homozygous</td><td colspan="1" rowspan="1">Mother and Father</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1"><xref ref-type="bibr" rid="MCS003756JIC31">Tummala et al. 2016</xref><break></break><xref ref-type="bibr" rid="MCS003756JIC4">Dhanraj et al. 2017</xref><break></break><xref ref-type="bibr" rid="MCS003756JIC2">Bluteau et al. 2018</xref></td></tr><tr><td colspan="1" rowspan="1">94<sup>b</sup></td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1"><italic>PLAA</italic></td><td colspan="1" rowspan="1">Chr 9:26,913,946</td><td colspan="1" rowspan="1">NM_001031689.3: c.1487-1G&gt;A</td><td colspan="1" rowspan="1">p.?</td><td colspan="1" rowspan="1">Substitution</td><td colspan="1" rowspan="1">Splice-site</td><td colspan="1" rowspan="1">rs1426488816</td><td colspan="1" rowspan="1">Homozygous</td><td colspan="1" rowspan="1">Mother and Father</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1"><xref ref-type="bibr" rid="MCS003756JIC7">Falik Zaccai et al. 2017</xref><break></break><xref ref-type="bibr" rid="MCS003756JIC12">Hall et al. 2017</xref></td></tr><tr><td colspan="1" rowspan="1">165<sup>a</sup></td><td colspan="1" rowspan="1">Singleton</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1"><italic>BCL11A</italic></td><td colspan="1" rowspan="1">Chr 2:60,773,339</td><td colspan="1" rowspan="1">NM_022893.3: c.152G&gt;C</td><td colspan="1" rowspan="1">p.Cys51Ser</td><td colspan="1" rowspan="1">Substitution</td><td colspan="1" rowspan="1">Missense</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">Heterozygous</td><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1">52<sup>d</sup></td><td colspan="1" rowspan="1"><xref ref-type="bibr" rid="MCS003756JIC5">Dias et al. 2016</xref><break></break><xref ref-type="bibr" rid="MCS003756JIC002">Cai et al. 2017</xref><break></break><xref ref-type="bibr" rid="MCS003756JIC034">Yoshida et al. 2018</xref></td></tr><tr><td colspan="1" rowspan="1">72<sup>a</sup></td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1"><italic>ATRX</italic><sup>c</sup></td><td colspan="1" rowspan="1">Chr X:76,776,310</td><td colspan="1" rowspan="1">NM_000489.4: c.7156C&gt;T</td><td colspan="1" rowspan="1">p.Arg2386*</td><td colspan="1" rowspan="1">Substitution</td><td colspan="1" rowspan="1">Nonsense</td><td colspan="1" rowspan="1">rs122445099</td><td colspan="1" rowspan="1">Hemizygous</td><td colspan="1" rowspan="1">Mother (heterozygous)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1"><xref ref-type="bibr" rid="MCS003756JIC23">Masliah-Planchon et al. 2018</xref><break></break><xref ref-type="bibr" rid="MCS003756JIC15">Ji et al. 2017</xref><break></break><xref ref-type="bibr" rid="MCS003756JIC28">Smolle et al. 2017</xref></td></tr><tr><td colspan="1" rowspan="1">135<sup>b</sup></td><td colspan="1" rowspan="1">Singleton</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1"><italic>RAD50</italic></td><td colspan="1" rowspan="1">Chr 5:131,931,451</td><td colspan="1" rowspan="1">NM_005732.3: c.2165dupA</td><td colspan="1" rowspan="1">p.Glu723Glyfs*5</td><td colspan="1" rowspan="1">Duplication</td><td colspan="1" rowspan="1">Frameshift</td><td colspan="1" rowspan="1">rs397507178</td><td colspan="1" rowspan="1">Heterozygous</td><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1">36</td><td colspan="1" rowspan="1"><xref ref-type="bibr" rid="MCS003756JIC13">Heikkinen et al. 2006</xref><break></break><xref ref-type="bibr" rid="MCS003756JIC32">Walsh et al. 2011</xref><break></break><xref ref-type="bibr" rid="MCS003756JIC0023">Lhota et al. 2016</xref><break></break><xref ref-type="bibr" rid="MCS003756JIC00023">Lin et al. 2016</xref></td></tr><tr><td colspan="1" rowspan="1">127<sup>b</sup></td><td colspan="1" rowspan="1">Trio</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1"><italic>ANK2</italic></td><td colspan="1" rowspan="1">Chr 4:114,186,083</td><td colspan="1" rowspan="1">NM_001148.4: c.1417C&gt;T</td><td colspan="1" rowspan="1">p.Arg473*</td><td colspan="1" rowspan="1">Substitution</td><td colspan="1" rowspan="1">Nonsense</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">Heterozygous</td><td colspan="1" rowspan="1">De novo</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1"><xref ref-type="bibr" rid="MCS003756JIC18">Koch et al. 2008</xref><break></break><xref ref-type="bibr" rid="MCS003756JIC33">Willsey et al. 2013</xref><break></break><xref ref-type="bibr" rid="MCS003756JIC14">Iossifov et al. 2012</xref><break></break><xref ref-type="bibr" rid="MCS003756JIC9">Farwell et al. 2015</xref></td></tr><tr><td colspan="1" rowspan="1">194<sup>b</sup></td><td colspan="1" rowspan="1">Singleton</td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1"><italic>FOXN1</italic></td><td colspan="1" rowspan="1">Chr 17:26,861,836</td><td colspan="1" rowspan="1">NM_003593.2: c.1247delC</td><td colspan="1" rowspan="1">p.Pro416Glnfs*134</td><td colspan="1" rowspan="1">Deletion</td><td colspan="1" rowspan="1">Frameshift</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">Heterozygous</td><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">Dominant inheritance not yet been published</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup>Diagnoses supported by later publications.</p></fn><fn><p><sup>b</sup>Cases with candidate variant/potential diagnoses.</p></fn><fn><p><sup>c</sup>Association between osteosarcoma and the <italic>ATRX</italic> germline pathogenic variant was not known at the time of WES analysis.</p></fn><fn><p><sup>d</sup>52nd place using Exomiser version 7.2.1 at the time of initial analysis in 2016, 1st place using Exomiser version 10.1.1 in the end of this study.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2c2"><title>Identification of Candidate Variants in ANK2, RAD50, and FOXN1</title><p>Unlike the above described cases, exome analysis revealed a de novo heterozygous nonsense NM_001148.4:c.1417C &gt; T (p.Arg473*) variant in the <italic>ANK2</italic> gene for Patient 127 (<xref ref-type="table" rid="MCS003756JITB4">Table 4</xref>) , who was referred for testing at age 5 yr with severe global developmental delay, seizures, aggressive behavior, and microcephaly. Pathogenic variants in <italic>ANK2</italic> are known to be associated with AD ankyrin-B-related cardiac arrhythmia and long QT syndrome 4 (MIM: 600919), which did not explain the patient's primary clinical concerns. However, Exomiser ranked this variant in the first place likely because of its de novo and truncating nature. RNA-seq expression data from the Genotype-Tissue Expression Project suggests that <italic>ANK2</italic> is expressed in brain tissue. Animal model experiments demonstrated that ank2 is required for synaptic stability in <italic>Drosophila</italic> (<xref ref-type="bibr" rid="MCS003756JIC18">Koch et al. 2008</xref>). Although the <italic>ANK2</italic> gene currently has not yet been associated with any human neurodevelopmental phenotypes in the OMIM database, there is more evidence supporting a correlation between a de novo <italic>ANK2</italic> variant and a human autism spectrum disorder and neurological phenotypes (<xref ref-type="bibr" rid="MCS003756JIC14">Iossifov et al. 2012</xref>; <xref ref-type="bibr" rid="MCS003756JIC33">Willsey et al. 2013</xref>; <xref ref-type="bibr" rid="MCS003756JIC9">Farwell et al. 2015</xref>; <xref ref-type="bibr" rid="MCS003756JIC30">Stessman et al. 2017</xref>). We therefore consider this de novo truncating variant in <italic>ANK2</italic> as a strong candidate to explain the patient's clinical phenotypes. More published data are needed to further support its association with a human neurological disorder.</p><p>Patient 135 had multiple primary tumors including unilateral retinoblastoma, astrocytoma, and a right shoulder granular cell tumor. <italic>RB1</italic> gene sequencing and deletion/duplication testing was negative. WES revealed a heterozygous NM_005732.3:c.2165dupA (p.Glu723Glyfs*5) variant in <italic>RAD50</italic> (<xref ref-type="table" rid="MCS003756JITB4">Table 4</xref>). Germline heterozygous <italic>RAD50</italic> loss-of-function mutations have been described in association with hereditary predisposition to cancers of the breast, ovary, fallopian tube, and peritoneum (<xref ref-type="bibr" rid="MCS003756JIC13">Heikkinen et al. 2006</xref>; <xref ref-type="bibr" rid="MCS003756JIC32">Walsh et al. 2011</xref>). Additionally, this variant is absent from the population data set gnomAD. However, based on currently available data, precise cancer risks associated with this gene are not well-described. It is also unclear whether germline pathogenic variants in <italic>RAD50</italic> are associated with an increased risk for retinoblastoma and pilocytic astrocytoma seen in this patient. Additional studies on the tumor and parental studies may further inform the association between the pathogenic variant in <italic>RAD50</italic> and the clinical presentation seen in this patient. We therefore considered this <italic>RAD50</italic> frameshift variant to be another candidate variant for this patient's predisposition to cancer.</p><p>Our Exomiser analysis also highlights potential discovery of a new inheritance pattern for known disease genes. An example is the identification of a heterozygous NM_003593.2:c.1247delC (p.Pro416Glnfs*134) frameshift variant in the <italic>FOXN1</italic> gene in a 22-d-old male with severe T-cell immunodeficiency, aplasia of the thymus, with normal B and NK cells (Patient 194; <xref ref-type="table" rid="MCS003756JITB4">Table 4</xref>). Pathogenic variants in <italic>FOXN1</italic> are associated with AR T-cell immunodeficiency, congenital alopecia, and nail dystrophy (MIM: 601705). Although exome coverage for the <italic>FOXN1</italic> exonic regions and splice-site junctions (5 bp into introns) was 100% at a minimum of 10× depth of coverage, a second possible variant, as expected for an AR disorder, was not identified by this analysis. The possibility this individual harbors a second variant, including a deletion or duplication of one or more exons or a variant in the intronic or regulatory regions that is undetectable by this test, cannot be excluded. However, a single heterozygous <italic>FOXN1</italic> truncating variant without a second hit using whole-genome sequencing was observed in a different patient with similar phenotypes (data not published), which suggests a potential dominant inheritance for disease. Although no functional studies have been performed to test the effects of this particular variant on <italic>FOXN1</italic> protein function or stability, this variant is expected to replace the carboxy-terminal portion of the <italic>FOXN1</italic> with 134 aberrant amino acids. Additionally, the variant is not present in the population database gnomAD. Given that this is a frameshift variant in a gene in which frameshift variants are likely to cause disease, and the absence of this type of variant in the general population, we consider this variant likely pathogenic. Further functional and parental studies are warranted to further clarify its pathogenicity and its potential dominant inheritance.</p></sec></sec><sec id="s2d"><title>WES Secondary Findings</title><p>Secondary findings deemed to be medically actionable were reported in nine of 101 patients who opted in to receive secondary findings (<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Table 1</ext-link>). These included variants within the 59 genes recommended by the ACMG (<xref ref-type="bibr" rid="MCS003756JIC16">Kalia et al. 2017</xref>), as well as pathogenic or likely pathogenic variants in <italic>MEFV</italic>, <italic>MYOC</italic>, and <italic>CHEK2</italic>. As expected, for incidental findings, the Exomiser rank was much lower than for those relevant to patients’ clinical phenotypes, with only 4/11 variants ranked between top 2 to 5.</p></sec><sec id="s2e"><title>Clinical Impact of Our Rapid WES Test</title><p>An accurate genetic diagnosis is essential for effective clinical management and may lead to modified treatment strategies, especially for pediatric patients compared to adults. We have implemented a WES workflow that allows for rapid diagnosis leading to improvements in patient management as exemplified by the following examples.</p><p>Patient 224 was an 11-mo-old male who presented with emesis, failure to thrive, hematochezia, and low serum concentration of IgG since age 5 mo. Endoscopy showed moderate to severe rectosigmoid colitis with ulcerations. The clinical picture was believed to reflect very early onset inflammatory bowel disease (VEO-IBD) prompting consideration of rare variants in <italic>NOD2</italic> or <italic>IL10RA</italic> and <italic>IL10RB</italic>. Expedited WES was pursued and a maternally inherited <italic>XIAP</italic> NM_001167.3:c.562G &gt; A (p.Gly188Arg) likely pathogenic hemizygous variant was identified. The results were returned to the ordering physician within 5 d. Follow-up targeted Sanger sequencing for the <italic>XIAP</italic> variant indicated that the mother was a heterozygous carrier for this variant who was not clinically affected. Pathogenic variants in <italic>XIAP</italic> are associated with X-linked recessive lymphoproliferative syndrome, type 2, which is characterized by primary immunodeficiency due to hemophagocytic lymphohistiocytosis and IBD. Allogeneic hematopoietic cell transplantation is the only curative treatment for this condition, and the patient's father is currently undergoing an evaluation to be a potential donor. This case highlights the ability to use WES to search beyond a narrow panel-based approach to obtain a diagnosis. In this case, and in similar ones reported previously (<xref ref-type="bibr" rid="MCS003756JIC17">Kelsen et al. 2015</xref>; <xref ref-type="bibr" rid="MCS003756JIC3">DeWeerdt 2016</xref>), a correct, early diagnosis markedly changed management (allogeneic hematopoietic cell transplantation) and prevented the patient from having to endure ineffective treatments.</p><p>Patient 104 was a 5-wk-old male with neonatal onset diffuse hypotonia in conjunction with muscle weakness, microcephaly, and respiratory distress. The infant was unable to be weaned from oxygen, had inspiratory stridor, and required nasogastric tube feeding. Decisions regarding placement of a gastrostomy tube and utility of a muscle biopsy for diagnosis prompted a request for an expedited WES, which was conducted within 1 wk. Exome sequencing revealed a hemizygous NM_000252.2:c.1262G &gt; T (p.Arg421Leu) pathogenic variant in <italic>MTM1</italic>, encoding myotubularin. Pathogenic variants in <italic>MTM1</italic> are associated with X-linked recessive myotubular myopathy (XLMTM). XLMTM presents prenatally with decreased fetal movements and polyhydramnios and affected males have significant motor delays and most fail to achieve independent ambulation. After informed discussion with the family, the treatment team proceeded with G tube placement and plans for long-term ventilatory support were discussed. The health-care management plans for this patient will include long-term follow-up care with a pulmonologist and neurologist. Annual evaluations with an ophthalmologist are indicated to screen for ophthalmoplegia, ptosis, and myopia. For this patient, the family had consented to receive incidental findings. A heterozygous NM_000218.2:c.1085A &gt; G (p.Lys362Arg) likely pathogenic variant in the <italic>KCNQ1</italic> gene was detected as an incidental finding. Pathogenic variants in <italic>KCNQ1</italic> are classically associated with long QT syndrome (MIM: 192500). This finding directly impacts follow-up and management of the patient, and further analysis revealed that the variant was inherited from the patient's father, who was then referred to a cardiologist for evaluation.</p></sec></sec><sec id="s3" sec-type="discussion"><title>DISCUSSION</title><sec id="s3a"><title>Incorporation of Exomiser into the Clinical Diagnostic Workflow Can Potentially Improve the Overall Diagnoses</title><p>Previous data have shown that phenotype-driven exome analysis and comparison of human to model organism phenotypes markedly improves the ability to identify candidate disease-causing variants (<xref ref-type="bibr" rid="MCS003756JIC35">Zemojtel et al. 2014</xref>; <xref ref-type="bibr" rid="MCS003756JIC27">Smedley et al. 2015</xref>). However, this approach has yet to be proven in a clinical diagnostic setting. Our group customized and validated multiple bioinformatics tools, including Exomiser, for clinical diagnosis. The algorithms use model species (e.g., mouse, fish, rat), functional data, and protein–protein association data for inferring gene–variant–disease association through phenotype-driven associations (<xref ref-type="bibr" rid="MCS003756JIC27">Smedley et al. 2015</xref>). By effectively utilizing available phenotypic information, functional data, and genomic knowledge, phenotype-driven strategies can improve efficiency and diagnostic yield. We used an earlier version of Exomiser (version 7.2.1) at the time of WES analysis and the latest version at the end of this study (version 10.1.1). Novel variants in candidate genes, including <italic>BPTF</italic>, <italic>DNAJC21</italic>, <italic>PLAA</italic>, <italic>BCL11A</italic>, <italic>ANK2</italic>, <italic>FOXN1</italic>, and <italic>RAD50</italic>, were identified or supported using this approach, which combined with updated literature sources allowed us to resolve an additional three cases. Our diagnostic yield of 36% includes the four patients with pathogenic or likely pathogenic variants in <italic>ATRX</italic>, <italic>BPTF</italic>, <italic>BCL11A</italic>, and <italic>DNAJC21</italic> as the phenotypes of these patients are consistent with the current literature (<xref ref-type="bibr" rid="MCS003756JIC5">Dias et al. 2016</xref>; <xref ref-type="bibr" rid="MCS003756JIC31">Tummala et al. 2016</xref>; <xref ref-type="bibr" rid="MCS003756JIC4">Dhanraj et al. 2017</xref>; <xref ref-type="bibr" rid="MCS003756JIC28">Smolle et al. 2017</xref>; <xref ref-type="bibr" rid="MCS003756JIC29">Stankiewicz et al. 2017</xref>; <xref ref-type="bibr" rid="MCS003756JIC23">Masliah-Planchon et al. 2018</xref>). In a conservative fashion, at this time we have not included the patients with variants in <italic>ANK2</italic>, <italic>RAD50</italic>, <italic>FOXN1</italic>, and <italic>PLAA</italic> as the gene–disease association has not been fully established (<italic>ANK2</italic>, <italic>RAD50</italic>); the clinical phenotypes of our patient do not fit completely with what have been previously described (<italic>PLAA</italic>); or the observed potential inheritance pattern has not yet been proven (<italic>FOXN1</italic>). We anticipate that others may identify and report patients with similar clinical phenotypes that have pathogenic variants in at least some of these genes, which would further increase our diagnostic rate.</p><sec id="s3a1"><title>Cancer Predisposition</title><p>In this case series, a total of five patients had a clinical indication for cancer predisposition (Patient 58, 72, 132, 135, and 174). Pathogenic or likely pathogenic variants were identified for four of the five patients (<xref ref-type="table" rid="MCS003756JITB3">Table 3</xref>); three of which (<italic>ATRX</italic>, <italic>DNAJC21</italic>, and <italic>RAD50</italic>) were novel at the time of analysis. Additionally, four pathogenic or likely pathogenic variants were identified in known cancer predisposition genes as incidental findings, including variants in <italic>RET</italic>, <italic>MEN1</italic>, <italic>BRCA2</italic>, and <italic>CHEK2</italic>. The total number of patients with findings in a cancer gene is higher than expected, given the unselected nature of this patient population. Identifying these patients may lead to modified treatment strategies in cases of syndrome-related increased toxicity or resistant disease. Cancer surveillance is warranted for at-risk relatives. Ultimately, systematic monitoring of patients and family members who have germline cancer predisposition variants may allow for detection of cancers at their earliest and most curable stage, thereby improving patient outcomes.</p></sec></sec><sec id="s3b"><title>Conclusion</title><p>We have implemented a phenotype-driven semiautomated workflow for WES at an academic children's hospital, which enables us to efficiently utilize WES in a frontline diagnostic setting. Aside from achieving a high diagnostic yield, we were able to reduce the turnaround time for clinical diagnosis, which impacts clinical management for a number of patients. Furthermore, the incorporation of Exomiser into the workflow has allowed us to identify a number of strong candidate variants and disease genes—some of which were supported by later publications. Combined, we established a successful WES workflow for increased diagnostic yield in the clinical setting, and strong evidence for novel variants in a research setting.</p></sec></sec><sec id="s4" sec-type="methods"><title>METHODS</title><sec id="s4a"><title>WES Workflow and Exomiser Validation</title><p>We established the workflow using 27 validation cases (<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Table 2</ext-link>). These include the HapMap trio samples (NA12878, NA12891, and NA12892), 25 singleton-WES, as well as 2 trio-WES (parents and affected child) cases with known pathogenic, likely pathogenic, and VUS selected by the clinical laboratory directors. The samples were coded and the data were processed and analyzed in a blinded manner to determine the analytical and clinical accuracy, respectively.</p><p>The FreeBayes variant caller failed to call a 13-bp deletion in the 5′ region of <italic>RB1</italic> exon 17 (NM_000321.2) for one case (<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Table 2</ext-link>, validation case 19). For the other 26 cases with 34 previously reported variants, including 27 pathogenic and likely pathogenic variants and seven VUSs, manual review of the exome data in a blinded manner achieved (26/26) 100% concordance rate with the prior diagnoses.</p><p>Additionally, we used Exomiser for 26 validation cases (except validation case 19) with known positive results. For pathogenic and likely pathogenic variants, Exomiser ranked 76% (22/29) variants in first place and 24% (7/29) in the second to sixth place. One likely pathogenic <italic>MLH1</italic> variant (Validation case 16) was reported as an incidental finding and was ranked in the sixth place under the AD model because of partial phenotype overlap. For the seven VUSs, Exomiser ranked three in the first place, one in the second place, one in the seventh place, one in the 16th place and one unranked (<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Table 2</ext-link>). For validation case 12, Exomiser initially ranked the known pathogenic variant in seventh place using a general HPO term “HP:0000819 Diabetes mellitus”. When a more specific HPO term “HP:0004904 Maturity-onset diabetes of the young” was used, however, the ranking was elevated to first place.</p></sec><sec id="s4b"><title>Clinical WES for Patients</title><p>A total of 106 consecutive, unselected patients were referred to the Center for Personalized Medicine (CPM) for WES testing from inpatient units and outpatient clinics at the Children's Hospital Los Angeles (CHLA) (<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Table 1</ext-link>). Genetic counseling and consent was required prior to WES and parents were provided with an option to receive incidental or secondary findings (<xref ref-type="bibr" rid="MCS003756JIC16">Kalia et al. 2017</xref>; <xref ref-type="bibr" rid="MCS003756JIC11">Green et al. 2013</xref>). This study was reviewed and approved by the CHLA Institutional Review Board.</p></sec><sec id="s4c"><title>Exome Sequencing Library Preparation, Sequencing, and Bioinformatics Pipeline</title><p>DNA was extracted from peripheral blood using a commercially available kit (Promega Maxwell RSC DNA Extraction Kit). The WES library was generated using the Agilent SureSelect Human All Exon V6 plus a custom mitochondrial genome capture kit, designed in collaboration with Agilent for consistent coverage across the mitochondrial genome (<xref ref-type="bibr" rid="MCS003756JIC8">Falk et al. 2012</xref>). Paired-end 2 × 100 bp sequencing was performed using the Illumina NextSeq 500 sequencing system. The overall exome sequencing workflow is illustrated in <xref ref-type="fig" rid="MCS003756JIF2">Figure 2</xref>, and the bioinformatics methodologies are detailed in the <ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Information</ext-link>. In brief, we used a combination of the bcbio pipeline (<uri xlink:href="https://github.com/chapmanb/bcbio-nextgen">https://github.com/chapmanb/bcbio-nextgen</uri>), custom scripts and open-source bioinformatics tools to fully automate quality control (QC), sequence alignment, coverage analysis, variant calling, and initial filtering based on ExAC (Exome Aggregation Consortium, <uri xlink:href="http://exac.broadinstitute.org/">http://exac.broadinstitute.org/</uri>) allele frequencies. The coverage statistics are summarized in <ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Figure 1</ext-link> and detailed in <ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Table 3</ext-link>. The variant statistics are detailed in <ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Information</ext-link>.</p><fig id="MCS003756JIF2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Clinical exome workflow at the Center for Personalized Medicine, Children's Hospital Los Angeles. Patients with a suspected genetic disease are recommended to undergo clinical exome sequencing after genetic counseling based on clinical evaluation and other available genetic test results. Variants generated from the bioinformatics pipeline for manual review are also processed via Exomiser. Candidate variants were then reviewed at the Exome Review Board before Sanger confirmation and final reporting.</p></caption><graphic xlink:href="MCS003756Ji_F2"></graphic></fig></sec><sec id="s4d"><title>Variant Calling with Edico DRAGEN Genome Pipeline</title><p>We also implemented the DRAGEN (Dynamic Read Analysis for Genomics) Genome pipeline from Edico Genome for fast FASTQ to VCF variant analysis, at roughly 4 min per exome. The DRAGEN provides hardware-accelerated analysis of next-generation sequencing (NGS) data using a field-programmable gate array (FPGA). We validated the DRAGEN Genome pipeline and achieved 99.4% and 99.9% sensitivity and specificity in overall variant calling when compared with Genome In A Bottle (GIAB; <uri xlink:href="https://www.nist.gov/programs-projects/genome-bottle">https://www.nist.gov/programs-projects/genome-bottle</uri>) calls, and 100% concordance rate for clinically significant variants for all 37 cases with positive findings.</p></sec><sec id="s4e"><title>Standardized Clinical Phenotype Encoding With HPO</title><p>For each patient, a list of phenotypic key words was generated by a clinical geneticist and a genetic counselor after review of the clinical and family history, requisition form and relevant medical notes which were then mapped to standardized HPO terms (<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Tables 1, 2</ext-link>; <xref ref-type="bibr" rid="MCS003756JIC19">Köhler et al. 2014</xref>, <xref ref-type="bibr" rid="MCS003756JIC20">2017</xref>; <xref ref-type="bibr" rid="MCS003756JIC25">Robinson et al. 2014</xref>) and captured in CPM's PhenoTips instance (<xref ref-type="bibr" rid="MCS003756JIC10">Girdea et al. 2013</xref>). A custom HPO annotator tool was used to facilitate the conversion of free-text clinical descriptions to matching HPO terms through natural language processing and weighted mapping of the descriptions against the tiered HPO terms, synonyms, and term definitions. With a free-text input of clinical phenotype descriptions, the HPO annotator prompts a list of potentially matching HPO terms through weighted mapping of the descriptions against the tiered universe of HPO term names, synonyms, and term definitions. Likely matching HPO terms are ranked by composite scores of semantic similarity. Those deemed to most accurately reflect the patient's clinical phenotype terms were selected, commented, and captured into CPM's PhenoTips instance. For downstream analysis, we also developed a custom and web-based system that generates the primary gene list based on HPO's frequent term-to-gene associations. In addition to the genes directly generated by the input term, we found genes for all the descendent terms, which are more specific, following the HPO tree structure.</p><p>A primary gene list was generated based on HPO's term-to-gene associations (<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Fig. 2</ext-link>; <xref ref-type="bibr" rid="MCS003756JIC10">Girdea et al. 2013</xref>).</p></sec><sec id="s4f"><title>Variant Filtration, Annotation, Analysis, and Interpretation</title><p>Variant filtration included three major steps. First, variants were restricted to the exonic regions and splice-site junctions (5 bp into the intron). Second, synonymous variants that were not previously reported as pathogenic in the Human Gene Mutation database (HGMD) and not predicted to alter splicing were filtered out. Last, common variants with minor allele frequency (MAF) of &gt;1% were filtered out. MAF is estimated using combined reference data sets: Genome Aggregation Database (gnomAD, <uri xlink:href="http://gnomad.broadinstitute.org">http://gnomad.broadinstitute.org</uri>) (after March 2017) and Exome Aggregation Consortium (ExAC, <uri xlink:href="http://exac.broadinstitute.org">http://exac.broadinstitute.org</uri>) (before March 2017). The remaining variants were annotated and analyzed using a commercial platform (Agilent Cartagenia Bench Lab NGS v5.0). For WES-trio, all de novo, homozygous, hemizygous (if male), and compound heterozygous variants were manually reviewed. For inherited heterozygous variants, only variants within the primary gene list were manually reviewed. For proband-only WES, all homozygous, hemizygous, and potentially compound heterozygous variants were manually reviewed. For heterozygous variants, only those within the primary gene list were manually reviewed. Additionally, all variants previously reported as disease-causing in the HGMD or ClinVar databases were reviewed. If a disease-causing variant was not identified, truncating variants in genes known to cause human diseases were reviewed. Each variant was interpreted with extensive database and literature review to consider clinical relevance, inheritance pattern, family segregation, disease mechanism, and variant level evidence (e.g., population allele frequency, evolutionary conservation, computational prediction, variant location) following ACMG standards and guidelines (<xref ref-type="bibr" rid="MCS003756JIC24">Richards et al. 2015</xref>). A variant interpretation checklist was used to ensure consistency.</p></sec><sec id="s4g"><title>Integration of Automated Exomiser Prioritization</title><p>In parallel with manual review, we incorporated an automated variant prioritization tool, Exomiser (<xref ref-type="bibr" rid="MCS003756JIC27">Smedley et al. 2015</xref>) (version 7.2.1 and subsequently 10.1.1), into our WES diagnostic workflow. The Exomiser application ranks genes and variants by combining clinical phenotype relevance and predictions as to whether the variant is deleterious (<xref ref-type="bibr" rid="MCS003756JIC27">Smedley et al. 2015</xref>). Variant prioritization is done with two methods, PhenIX and hiPHIVE, for each of three inheritance models: AD, AR and X-linked. PhenIX is based on known gene–disease associations in humans and is therefore more suitable for clinical diagnosis; hiPHIVE uses supporting evidence from functional studies in model species and protein-to-protein associations, and therefore has the potential for novel disease gene discovery. Four filters (target, frequency, pathogenicity, and inheritance) were applied to the candidate variants. All variants that were filtered out were not ranked. The remaining candidate variants were numerically ranked from the first to the final number of variants.</p></sec><sec id="s4h"><title>Exome Board Review</title><p>Relevant candidate variants selected from both manual review and the top 20 candidate variants ranked by Exomiser were reviewed in the context of patients’ clinical phenotypes at the Exome Review Board. This board includes ordering physicians, clinical geneticists, laboratory directors, bioinformaticians, and genetic counselors.</p></sec><sec id="s4i"><title>Sanger Sequencing Confirmation and Follow-Up Family Segregation Studies</title><p>Sanger sequencing was performed to confirm all the clinically relevant variants prior to final reporting and for follow-up family segregation studies.</p></sec></sec><sec id="s5"><title>ADDITIONAL INFORMATION</title><sec id="s5a" sec-type="data-availability"><title>Data Deposition and Access</title><p>Variants reported in this study have been detailed in the <ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003756/-/DC1">Supplemental Tables</ext-link>. Variants have also been deposited at NCBI ClinVar (<uri xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/">https://www.ncbi.nlm.nih.gov/clinvar/</uri>) under accession numbers SCV0006800 92.1, SCV000692541.1–SCV000692559.1, and SCV000854432.1–SCV000854564.1. Raw sequencing data is not available under the IRB used to perform this study.</p></sec><sec id="s5b"><title>Ethics Statement</title><p>All testing performed was part of clinical patient management and not on a research basis. The study was approved by the Children's Hospital Los Angeles Institutional Review Board (CHLA-17-00374: CPM Exome Study).</p></sec><sec id="s5c"><title>Acknowledgments</title><p>The authors gratefully acknowledge extremely valuable scientific discussions with our clinical colleagues Drs. Alvaro Serrano, Amy Yeh, Andrew Dietz, Ashley Margol, Ashwini Lakshmanan, Caitlin Montgomery, Catherine Karimov, Cecilia Fu, Cheryl Lew, Christopher Kuo, Cindy Wong, Daniela Schweitzer, Deborah Holder, Deborah Krakow, Debra Stern, Denizhan H. Akan, Derek Wong, Diana Ferman, Divya Vats, Elizabeth Vandyke, Erin Lee, Etai Adam, Eugenia Ho, Eunice Hagen, Gail Hubbard, Jamie Frediani, Jay Desai, Jennifer Cotter, Jonathan Tam, Joseph A. Church, Julie Jaffray, Jyes Querubin, Kathryn Fletcher, Kathy Langevin, Kiarash Sadrieh, Leigh Ramos-Platt, Leo Mascarenhas, Linda Randolph, Manvi Bansal, Mark Borchert, Mark Selleck, Matt Lallas, Mattew Oberley, Megan Langille, Melinda Braskett, Michele Van Hirtum-Das, Naim Salama, Neena Kapoor, Nusrat Ahsan, Pedro Sanchez, Phillippe Friedlich, Pisit Pitukcheewanont, Quyen Luc, Rachel Chapman, Rebecca DeMaria, Rebecca Ellen Meyer, Robert Vasko, Ronald Ferdman, Saranya Veluswamy, Srikumar Nair, Susanna Sorrentino, Tena L. Rosser, Theodora Stavroudis, Thomas Hofstra, Tiffany Restelli, Van Hirtum-Das, and Wendy Mitchell. In addition, we thank David Ruble, Yuxia Zhan, Cindy Fong, Vandana Mehta, Dejerianne Ostrow, and the clinical laboratory team for their technical assistance.</p></sec><sec id="s5d"><title>Author Contributions</title><p>J.A.B. and X.G. conceived and supervised the study. J.J. led the study and performed the bulk of variant interpretations according to the ACMG guideline. J.B., D.T.M., and M.B. carried out all analytical tasks while validating the exome data analysis pipeline. M.B. implemented exome data analysis pipeline and performed sequence analysis and variant calling. L.S. implemented bioinformatics tools for mapping clinical descriptions to HPO terms and performed Exomiser analysis. T.T. computationally determined the genetic ancestry of all cases. C.Q., G.R., and S.C.S. contributed to phenotype ascertainment and variant interpretation. All authors participated in the Exome Review Board and contributed to acquisition, analysis, and interpretation of data. J.J., J.A.B., and X.G. drafted the manuscript. All authors contributed to the development of the manuscript.</p></sec><sec id="s5e"><title>Funding</title><p>This study was supported by the Department of Pathology and Laboratory Medicine at the Children's Hospital Los Angeles.</p></sec><sec id="s5f"><title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></sec></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="PMC_1">
<caption>
<title>Supplemental Material</title>
</caption>
<media mime-subtype="html" mimetype="text" xlink:href="supp_5_2_a003756__index.html"></media>
<media mime-subtype="tiff" mimetype="image" xlink:href="supp_mcs.a003756_Supplemental_Figure_1.tif" xlink:role="associated-file"></media>
<media mime-subtype="tiff" mimetype="image" xlink:href="supp_mcs.a003756_Supplemental_Figure_2.tif" xlink:role="associated-file"></media>
<media mime-subtype="msword" mimetype="application" xlink:href="supp_mcs.a003756_Supplemental_Information.docx" xlink:role="associated-file"></media>
<media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="supp_mcs.a003756_Supplemental_Table_1.xlsx" xlink:role="associated-file"></media>
<media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="supp_mcs.a003756_Supplemental_Table_2.xlsx" xlink:role="associated-file"></media>
<media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="supp_mcs.a003756_Supplemental_Table_3.xls" xlink:role="associated-file"></media>
</supplementary-material>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="supplementary-material">
<p>[Supplemental material is available for this article.]</p>
</fn>
</fn-group>
<ref-list>
<title>REFERENCES</title>
<ref id="MCS003756JIC1">
<mixed-citation publication-type="journal"><string-name><surname>Bamshad</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Ng</surname>
<given-names>SB</given-names></string-name>, <string-name><surname>Bigham</surname>
<given-names>AW</given-names></string-name>, <string-name><surname>Tabor</surname>
<given-names>HK</given-names></string-name>, <string-name><surname>Emond</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Nickerson</surname>
<given-names>DA</given-names></string-name>, <string-name><surname>Shendure</surname>
<given-names>J</given-names></string-name>. <year>2011</year>
<article-title>Exome sequencing as a tool for Mendelian disease gene discovery</article-title>. <source/>Nat Rev Genet
<volume>12</volume>: <fpage>745</fpage>–<lpage>755</lpage>. <pub-id pub-id-type="doi">10.1038/nrg3031</pub-id><pub-id pub-id-type="pmid">21946919</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC2">
<mixed-citation publication-type="journal"><string-name><surname>Bluteau</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Sebert</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Leblanc</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Peffault de Latour</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Quentin</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lainey</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Hernandez</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Dalle</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Sicre de Fontbrune</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Lengline</surname>
<given-names>E</given-names></string-name>, <etal></etal>
<year>2018</year>
<article-title>A landscape of germ line mutations in a cohort of inherited bone marrow failure patients</article-title>. <source/>Blood
<volume>131</volume>: <fpage>717</fpage>–<lpage>732</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2017-09-806489</pub-id><pub-id pub-id-type="pmid">29146883</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC002">
<mixed-citation publication-type="journal"><string-name><surname>Cai</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Xiang</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>He</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Sun</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>PP</given-names></string-name>. <year>2017</year>
<article-title>Identification of novel mutations in the HbF repressor gene <italic>BCL11A</italic> in patients with autism and intelligence disabilities</article-title>. <source/>Am J Hematol
<volume>92</volume>: <fpage>E653</fpage>–<lpage>E656</lpage>.<pub-id pub-id-type="pmid">28891213</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC3">
<mixed-citation publication-type="journal"><string-name><surname>Deweerdt</surname>
<given-names>S</given-names></string-name>. <year>2016</year>
<article-title>Genetics: clues in the code</article-title>. <source/>Nature
<volume>540</volume>: <fpage>S104</fpage>–<lpage>S105</lpage>. <pub-id pub-id-type="doi">10.1038/540s104a</pub-id><pub-id pub-id-type="pmid">28002395</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC4">
<mixed-citation publication-type="journal"><string-name><surname>Dhanraj</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Matveev</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Lauhasurayotin</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Jardine</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Cada</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zlateska</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Tailor</surname>
<given-names>CS</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Mendoza-Londono</surname>
<given-names>R</given-names></string-name>, <etal></etal>
<year>2017</year>
<article-title>Biallelic mutations in <italic>DNAJC21</italic> cause Shwachman</article-title>–<article-title>Diamond syndrome</article-title>. <source/>Blood
<volume>129</volume>: <fpage>1557</fpage>–<lpage>1562</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2016-08-735431</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC5">
<mixed-citation publication-type="journal"><string-name><surname>Dias</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Estruch</surname>
<given-names>SB</given-names></string-name>, <string-name><surname>Graham</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>McRae</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Sawiak</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Hurst</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Joss</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Holder</surname>
<given-names>SE</given-names></string-name>, <string-name><surname>Morton</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Turner</surname>
<given-names>C</given-names></string-name>, <etal></etal>
<year>2016</year>
<article-title><italic>BCL11A</italic> haploinsufficiency causes an intellectual disability syndrome and dysregulates transcription</article-title>. <source/>Am J Hum Genet
<volume>99</volume>: <fpage>253</fpage>–<lpage>274</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2016.05.030</pub-id><pub-id pub-id-type="pmid">27453576</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC6">
<mixed-citation publication-type="journal"><string-name><surname>Dragojlovic</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Elliott</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Adam</surname>
<given-names>S</given-names></string-name>, <string-name><surname>van Karnebeek</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Lehman</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mwenifumbo</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Nelson</surname>
<given-names>TN</given-names></string-name>, <string-name><surname>du Souich</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Friedman</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Lynd</surname>
<given-names>LD</given-names></string-name>. <year>2018</year>
<article-title>The cost and diagnostic yield of exome sequencing for children with suspected genetic disorders: a benchmarking study</article-title>. <source/>Genet Med
<volume>20</volume>: <fpage>1013</fpage>–<lpage>1021</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2017.226</pub-id><pub-id pub-id-type="pmid">29300375</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC7">
<mixed-citation publication-type="journal"><string-name><surname>Falik Zaccai</surname>
<given-names>TC</given-names></string-name>, <string-name><surname>Savitzki</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Zivony-Elboum</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Vilboux</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Fitts</surname>
<given-names>EC</given-names></string-name>, <string-name><surname>Shoval</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kalfon</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Samra</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Keren</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Gross</surname>
<given-names>B</given-names></string-name>, <etal></etal>
<year>2017</year>
<article-title>Phospholipase A<sub>2</sub>-activating protein is associated with a form of leukoencephalopathy</article-title>. <source/>Brain
<volume>149</volume>: <fpage>370</fpage>–<lpage>386</lpage>. <pub-id pub-id-type="doi">10.1093/brain/aww295</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC8">
<mixed-citation publication-type="journal"><string-name><surname>Falk</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Pierce</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Consugar</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Xie</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Guadalupe</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hardy</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Rappaport</surname>
<given-names>EF</given-names></string-name>, <string-name><surname>Wallace</surname>
<given-names>DC</given-names></string-name>, <string-name><surname>LeProust</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Gai</surname>
<given-names>X</given-names></string-name>. <year>2012</year>
<article-title>Mitochondrial disease genetic diagnostics: optimized whole-exome analysis for all MitoCarta nuclear genes and the mitochondrial genome</article-title>. <source/>Discov Med
<volume>14</volume>: <fpage>389</fpage>–<lpage>399</lpage>.<pub-id pub-id-type="pmid">23272691</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC9">
<mixed-citation publication-type="journal"><string-name><surname>Farwell</surname>
<given-names>KD</given-names></string-name>, <string-name><surname>Shahmirzadi</surname>
<given-names>L</given-names></string-name>, <string-name><surname>El-Khechen</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Powis</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Chao</surname>
<given-names>EC</given-names></string-name>, <string-name><surname>Tippin Davis</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Baxter</surname>
<given-names>RM</given-names></string-name>, <string-name><surname>Zeng</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Mroske</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Parra</surname>
<given-names>MC</given-names></string-name>, <etal></etal>
<year>2015</year>
<article-title>Enhanced utility of family-centered diagnostic exome sequencing with inheritance model–based analysis: results from 500 unselected families with undiagnosed genetic conditions</article-title>. <source/>Genet Med
<volume>17</volume>: <fpage>578</fpage>–<lpage>586</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2014.154</pub-id><pub-id pub-id-type="pmid">25356970</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC10">
<mixed-citation publication-type="journal"><string-name><surname>Girdea</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Dumitriu</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fiume</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bowdin</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Boycott</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Chénier</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Chitayat</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Faghfoury</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Meyn</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Ray</surname>
<given-names>PN</given-names></string-name>, <etal></etal>
<year>2013</year>
<article-title>PhenoTips: patient phenotyping software for clinical and research use</article-title>. <source/>Hum Mutat
<volume>34</volume>: <fpage>1057</fpage>–<lpage>1065</lpage>. <pub-id pub-id-type="doi">10.1002/humu.22347</pub-id><pub-id pub-id-type="pmid">23636887</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC11">
<mixed-citation publication-type="journal"><string-name><surname>Green</surname>
<given-names>RC</given-names></string-name>, <string-name><surname>Berg</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Grody</surname>
<given-names>WW</given-names></string-name>, <string-name><surname>Kalia</surname>
<given-names>SS</given-names></string-name>, <string-name><surname>Korf</surname>
<given-names>BR</given-names></string-name>, <string-name><surname>Martin</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>McGuire</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>Nussbaum</surname>
<given-names>RL</given-names></string-name>, <string-name><surname>O'Daniel</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Ormond</surname>
<given-names>KE</given-names></string-name>, <etal></etal>
<year>2013</year>
<article-title>ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing</article-title>. <source/>Genet Med
<volume>15</volume>: <fpage>565</fpage>–<lpage>574</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2013.73</pub-id><pub-id pub-id-type="pmid">23788249</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC12">
<mixed-citation publication-type="journal"><string-name><surname>Hall</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Nahorski</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Murray</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Shaheen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Perkins</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Dissanayake</surname>
<given-names>KN</given-names></string-name>, <string-name><surname>Kristaryanto</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Jones</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Vogt</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rivagorda</surname>
<given-names>M</given-names></string-name>, <etal></etal>
<year>2017</year>
<article-title>PLAA mutations cause a lethal infantile epileptic encephalopathy by disrupting ubiquitin-mediated endolysosomal degradation of synaptic proteins</article-title>. <source/>Am J Hum Genet
<volume>100</volume>: <fpage>706</fpage>–<lpage>724</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2017.03.008</pub-id><pub-id pub-id-type="pmid">28413018</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC13">
<mixed-citation publication-type="journal"><string-name><surname>Heikkinen</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Rapakko</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Karppinen</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Erkko</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Knuutila</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lundán</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Mannermaa</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Børresen-Dale</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>Borg</surname>
<given-names>Å</given-names></string-name>, <string-name><surname>Barkardottir</surname>
<given-names>RB</given-names></string-name>, <etal></etal>
<year>2006</year>
<article-title><italic>RAD50</italic> and <italic>NBS1</italic> are breast cancer susceptibility genes associated with genomic instability</article-title>. <source/>Carcinogenesis
<volume>27</volume>: <fpage>1593</fpage>–<lpage>1599</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/bgi360</pub-id><pub-id pub-id-type="pmid">16474176</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC14">
<mixed-citation publication-type="journal"><string-name><surname>Iossifov</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Ronemus</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Levy</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Hakker</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Rosenbaum</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Yamrom</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>YH</given-names></string-name>, <string-name><surname>Narzisi</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Leotta</surname>
<given-names>A</given-names></string-name>, <etal></etal>
<year>2012</year>
<article-title>De novo gene disruptions in children on the autistic spectrum</article-title>. <source/>Neuron
<volume>74</volume>: <fpage>285</fpage>–<lpage>299</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2012.04.009</pub-id><pub-id pub-id-type="pmid">22542183</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC15">
<mixed-citation publication-type="journal"><string-name><surname>Ji</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Quindipan</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Parham</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Shen</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Ruble</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Bootwalla</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Maglinte</surname>
<given-names>DT</given-names></string-name>, <string-name><surname>Gai</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Saitta</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Biegel</surname>
<given-names>JA</given-names></string-name>, <etal></etal>
<year>2017</year>
<article-title>Inherited germline <italic>ATRX</italic> mutation in two brothers with ATR-X syndrome and osteosarcoma</article-title>. <source/>Am J Med Genet A
<volume>173</volume>: <fpage>1390</fpage>–<lpage>1395</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.38184</pub-id><pub-id pub-id-type="pmid">28371217</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC16">
<mixed-citation publication-type="journal"><string-name><surname>Kalia</surname>
<given-names>SS</given-names></string-name>, <string-name><surname>Adelman</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Bale</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Chung</surname>
<given-names>WK</given-names></string-name>, <string-name><surname>Eng</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Evans</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Herman</surname>
<given-names>GE</given-names></string-name>, <string-name><surname>Hufnagel</surname>
<given-names>SB</given-names></string-name>, <string-name><surname>Klein</surname>
<given-names>TE</given-names></string-name>, <string-name><surname>Korf</surname>
<given-names>BR</given-names></string-name>, <etal></etal>
<year>2017</year>
<article-title>Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics</article-title>. <source/>Genet Med
<volume>19</volume>: <fpage>249</fpage>–<lpage>255</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2016.190</pub-id><pub-id pub-id-type="pmid">27854360</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC17">
<mixed-citation publication-type="journal"><string-name><surname>Kelsen</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Dawany</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Martinez</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Grochowski</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Maurer</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Rappaport</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Piccoli</surname>
<given-names>DA</given-names></string-name>, <string-name><surname>Baldassano</surname>
<given-names>RN</given-names></string-name>, <string-name><surname>Mamula</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Sullivan</surname>
<given-names>KE</given-names></string-name>, <etal></etal>
<year>2015</year>
<article-title>A de novo whole gene deletion of XIAP detected by exome sequencing analysis in very early onset inflammatory bowel disease: a case report</article-title>. <source/>BMC Gastroenterol
<volume>15</volume>: <fpage>179</fpage>
<pub-id pub-id-type="doi">10.1186/s12876-015-0394-z</pub-id><pub-id pub-id-type="pmid">26683620</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC18">
<mixed-citation publication-type="journal"><string-name><surname>Koch</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Schwarz</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Beuchle</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Goellner</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Langegger</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Aberle</surname>
<given-names>H</given-names></string-name>. <year>2008</year>
<article-title><italic>Drosophila</italic> ankyrin 2 is required for synaptic stability</article-title>. <source/>Neuron
<volume>58</volume>: <fpage>210</fpage>–<lpage>222</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2008.03.019</pub-id><pub-id pub-id-type="pmid">18439406</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC19">
<mixed-citation publication-type="journal"><string-name><surname>Köhler</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Doelken</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Mungall</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Bauer</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Firth</surname>
<given-names>HV</given-names></string-name>, <string-name><surname>Bailleul-Forestier</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Black</surname>
<given-names>GC</given-names></string-name>, <string-name><surname>Brown</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Brudno</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Campbell</surname>
<given-names>J</given-names></string-name>, <etal></etal>
<year>2014</year>
<article-title>The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data</article-title>. <source/>Nucleic Acids Res
<volume>42</volume>: <fpage>D966</fpage>–<lpage>D974</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt1026</pub-id><pub-id pub-id-type="pmid">24217912</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC20">
<mixed-citation publication-type="journal"><string-name><surname>Köhler</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Vasilevsky</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Engelstad</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Foster</surname>
<given-names>E</given-names></string-name>, <string-name><surname>McMurry</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Aymé</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Baynam</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Bello</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Boerkoel</surname>
<given-names>CF</given-names></string-name>, <string-name><surname>Boycott</surname>
<given-names>KM</given-names></string-name>, <etal></etal>
<year>2017</year>
<article-title>The Human Phenotype Ontology in 2017</article-title>. <source/>Nucleic Acids Res
<volume>45</volume>: <fpage>D865</fpage>–<lpage>D876</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkw1039</pub-id><pub-id pub-id-type="pmid">27899602</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC21">
<mixed-citation publication-type="journal"><string-name><surname>Ku</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Cooper</surname>
<given-names>DN</given-names></string-name>, <string-name><surname>Polychronakos</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Naidoo</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Soong</surname>
<given-names>R</given-names></string-name>. <year>2012</year>
<article-title>Exome sequencing: dual role as a discovery and diagnostic tool</article-title>. <source/>Ann Neurol
<volume>71</volume>: <fpage>5</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1002/ana.22647</pub-id><pub-id pub-id-type="pmid">22275248</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC22">
<mixed-citation publication-type="journal"><string-name><surname>Lee</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Deignan</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Dorrani</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Strom</surname>
<given-names>SP</given-names></string-name>, <string-name><surname>Kantarci</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Quintero-Rivera</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Das</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Toy</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Harry</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Yourshaw</surname>
<given-names>M</given-names></string-name>, <etal></etal>
<year>2014</year>
<article-title>Clinical exome sequencing for genetic identification of rare Mendelian disorders</article-title>. <source/>JAMA
<volume>312</volume>: <fpage>1880</fpage>–<lpage>1887</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2014.14604</pub-id><pub-id pub-id-type="pmid">25326637</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC0023">
<mixed-citation publication-type="journal"><string-name><surname>Lhota</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Zemankova</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Kleiblova</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Soukupova</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Vocka</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Stranecky</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Janatova</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hartmannova</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Hodanova</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Kmoch</surname>
<given-names>S</given-names></string-name>, <etal></etal>
<year>2016</year>
<article-title>Hereditary truncating mutations of DNA repair and other genes in <italic>BRCA1/BRCA2/PALB2</italic>-negatively tested breast cancer patients</article-title>. <source/>Clin Genet
<volume>90</volume>: <fpage>324</fpage>–<lpage>333</lpage>.<pub-id pub-id-type="pmid">26822949</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC00023">
<mixed-citation publication-type="journal"><string-name><surname>Lin</surname>
<given-names>PH</given-names></string-name>, <string-name><surname>Kuo</surname>
<given-names>WH</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Lu</surname>
<given-names>YS</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Kuo</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>MY</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>CY</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>FT</given-names></string-name>, <string-name><surname>Yeh</surname>
<given-names>MH</given-names></string-name>, <etal></etal>
<year>2016</year>
<article-title>Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer</article-title>. <source/>Oncotarget
<volume>7</volume>: <fpage>8310</fpage>–<lpage>8320</lpage>.<pub-id pub-id-type="pmid">26824983</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC23">
<mixed-citation publication-type="journal"><string-name><surname>Masliah-Planchon</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lévy</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Héron</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Giuliano</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Badens</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Fréneaux</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Galmiche</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Guinebretierre</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Cellier</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Waterfall</surname>
<given-names>JJ</given-names></string-name>, <etal></etal>
<year>2018</year>
<article-title>Does ATRX germline variation predispose to osteosarcoma? Three additional cases of osteosarcoma in two ATR-X syndrome patients</article-title>. <source/>Eur J Hum Genet
<volume>26</volume>: <fpage>1217</fpage>–<lpage>1221</lpage>. <pub-id pub-id-type="doi">10.1038/s41431-018-0147-x</pub-id><pub-id pub-id-type="pmid">29706636</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC24">
<mixed-citation publication-type="journal"><string-name><surname>Richards</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Aziz</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Bale</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Bick</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Das</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gastier-Foster</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Grody</surname>
<given-names>WW</given-names></string-name>, <string-name><surname>Hegde</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Lyon</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Spector</surname>
<given-names>E</given-names></string-name>, <etal></etal>
<year>2015</year>
<article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>. <source/>Genet Med
<volume>17</volume>: <fpage>405</fpage>–<lpage>423</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2015.30</pub-id><pub-id pub-id-type="pmid">25741868</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC25">
<mixed-citation publication-type="journal"><string-name><surname>Robinson</surname>
<given-names>PN</given-names></string-name>, <string-name><surname>Köhler</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Oellrich</surname>
<given-names>A</given-names></string-name>; <collab>Sanger Mouse Genetics Project</collab>, <string-name><surname>Wang</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Mungall</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Lewis</surname>
<given-names>SE</given-names></string-name>, <string-name><surname>Washington</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Bauer</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Seelow</surname>
<given-names>D</given-names></string-name>, <etal></etal> (<year>2014</year>). <article-title>Improved exome prioritization of disease genes through cross-species phenotype comparison</article-title>. <source/>Genome Res
<volume>24</volume>: <fpage>340</fpage>–<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1101/gr.160325.113</pub-id><pub-id pub-id-type="pmid">24162188</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC26">
<mixed-citation publication-type="journal"><string-name><surname>Smedley</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Robinson</surname>
<given-names>PN</given-names></string-name>. <year>2015</year>
<article-title>Phenotype-driven strategies for exome prioritization of human Mendelian disease genes</article-title>. <source/>Genome Med
<volume>7</volume>: <fpage>81</fpage>
<pub-id pub-id-type="doi">10.1186/s13073-015-0199-2</pub-id><pub-id pub-id-type="pmid">26229552</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC27">
<mixed-citation publication-type="journal"><string-name><surname>Smedley</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Jacobsen</surname>
<given-names>JO</given-names></string-name>, <string-name><surname>Jäger</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Köhler</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Holtgrewe</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Schubach</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Siragusa</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Zemojtel</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Buske</surname>
<given-names>OJ</given-names></string-name>, <string-name><surname>Washington</surname>
<given-names>NL</given-names></string-name>, <etal></etal>
<year>2015</year>
<article-title>Next-generation diagnostics and disease-gene discovery with the Exomiser</article-title>. <source/>Nat Protoc
<volume>10</volume>: <fpage>2004</fpage>–<lpage>2015</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2015.124</pub-id><pub-id pub-id-type="pmid">26562621</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC28">
<mixed-citation publication-type="journal"><string-name><surname>Smolle</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Heitzer</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Geigl</surname>
<given-names>JB</given-names></string-name>, <string-name><surname>Al-Kaissi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Liegl-Atzwanger</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Seidel</surname>
<given-names>MG</given-names></string-name>, <string-name><surname>Holzer</surname>
<given-names>LA</given-names></string-name>, <string-name><surname>Leithner</surname>
<given-names>A</given-names></string-name>. <year>2017</year>
<article-title>A novel mutation in <italic>ATRX</italic> associated with intellectual disability, syndromic features, and osteosarcoma</article-title>. <source/>Pediatr Blood Cancer
<volume>64</volume>: <fpage>e26522</fpage>
<pub-id pub-id-type="doi">10.1002/pbc.26522</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC29">
<mixed-citation publication-type="journal"><string-name><surname>Stankiewicz</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Khan</surname>
<given-names>TN</given-names></string-name>, <string-name><surname>Szafranski</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Slattery</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Streff</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Vetrini</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Bernstein</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Brown</surname>
<given-names>CW</given-names></string-name>, <string-name><surname>Rosenfeld</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Rednam</surname>
<given-names>S</given-names></string-name>, <etal></etal>
<year>2017</year>
<article-title>Haploinsufficiency of the chromatin remodeler <italic>BPTF</italic> causes syndromic developmental and speech delay, postnatal microcephaly, and dysmorphic features</article-title>. <source/>Am J Hum Genet
<volume>101</volume>: <fpage>503</fpage>–<lpage>515</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2017.08.014</pub-id><pub-id pub-id-type="pmid">28942966</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC30">
<mixed-citation publication-type="journal"><string-name><surname>Stessman</surname>
<given-names>HA</given-names></string-name>, <string-name><surname>Xiong</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Coe</surname>
<given-names>BP</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Hoekzema</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Fenckova</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kvarnung</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gerdts</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Trinh</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Cosemans</surname>
<given-names>N</given-names></string-name>, <etal></etal>
<year>2017</year>
<article-title>Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases</article-title>. <source/>Nat Genet
<volume>49</volume>: <fpage>515</fpage>–<lpage>526</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3792</pub-id><pub-id pub-id-type="pmid">28191889</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC31">
<mixed-citation publication-type="journal"><string-name><surname>Tummala</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Walne</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Williams</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bockett</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Collopy</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Cardoso</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ellison</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Wynn</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Leblanc</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Fitzgibbon</surname>
<given-names>J</given-names></string-name>, <etal></etal>
<year>2016</year>
<article-title><italic>DNAJC21</italic> mutations link a cancer-prone bone marrow failure syndrome to corruption in 60S ribosome subunit maturation</article-title>. <source/>Am J Hum Genet
<volume>99</volume>: <fpage>115</fpage>–<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2016.05.002</pub-id><pub-id pub-id-type="pmid">27346687</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC32">
<mixed-citation publication-type="journal"><string-name><surname>Walsh</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Casadei</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>MK</given-names></string-name>, <string-name><surname>Pennil</surname>
<given-names>CC</given-names></string-name>, <string-name><surname>Nord</surname>
<given-names>AS</given-names></string-name>, <string-name><surname>Thornton</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Roeb</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Agnew</surname>
<given-names>KJ</given-names></string-name>, <string-name><surname>Stray</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Wickramanayake</surname>
<given-names>A</given-names></string-name>, <etal></etal>
<year>2011</year>
<article-title>Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing</article-title>. <source/>Proc Natl Acad Sci
<volume>108</volume>: <fpage>18032</fpage>–<lpage>18037</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1115052108</pub-id><pub-id pub-id-type="pmid">22006311</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC33">
<mixed-citation publication-type="journal"><string-name><surname>Willsey</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Sanders</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Dong</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tebbenkamp</surname>
<given-names>AT</given-names></string-name>, <string-name><surname>Muhle</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Reilly</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Fertuzinhos</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Miller</surname>
<given-names>JA</given-names></string-name>, <etal></etal>
<year>2013</year>
<article-title>Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism</article-title>. <source/>Cell
<volume>155</volume>: <fpage>997</fpage>–<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2013.10.020</pub-id><pub-id pub-id-type="pmid">24267886</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC34">
<mixed-citation publication-type="journal"><string-name><surname>Yang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Muzny</surname>
<given-names>DM</given-names></string-name>, <string-name><surname>Xia</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Niu</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Person</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Ding</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Ward</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Braxton</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Buhay</surname>
<given-names>C</given-names></string-name>, <etal></etal>
<year>2014</year>
<article-title>Molecular findings among patients referred for clinical whole-exome sequencing</article-title>. <source/>JAMA
<volume>312</volume>: <fpage>1870</fpage>–<lpage>1879</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2014.14601</pub-id><pub-id pub-id-type="pmid">25326635</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC034">
<mixed-citation publication-type="journal"><string-name><surname>Yoshida</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Nakashima</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Okanishi</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Kanai</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fujimoto</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Itomi</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Morimoto</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Saitsu</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Kato</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Matsumoto</surname>
<given-names>N</given-names></string-name>, <etal></etal>
<year>2018</year>
<article-title>Identification of novel <italic>BCL11A</italic> variants in patients with epileptic encephalopathy: expanding the phenotypic spectrum</article-title>. <source/>Clin Genet
<volume>93</volume>: <fpage>368</fpage>–<lpage>373</lpage>.<pub-id pub-id-type="pmid">28589569</pub-id></mixed-citation>
</ref>
<ref id="MCS003756JIC35">
<mixed-citation publication-type="journal"><string-name><surname>Zemojtel</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Köhler</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mackenroth</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Jäger</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hecht</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Krawitz</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Graul-Neumann</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Doelken</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ehmke</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Spielmann</surname>
<given-names>M</given-names></string-name>, <etal></etal>
<year>2014</year>
<article-title>Effective diagnosis of genetic disease by computational phenotype analysis of the disease-associated genome</article-title>. <source/>Sci Transl Med
<volume>6</volume>: <fpage>252ra123</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.3009262</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>